Exporter

You can select particular sections to be included in the output file.
EN
FR

Liste modèle des médicaments essentiels

Trouvé 1417 recommandations pour 667 médicaments et 153 équivalents thérapeutiques
Les recommandations supprimées et les demandes rejetées sont affichées. Les cacher.
  1. BCG vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tuberculosis
  2. Ebola vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  3. Japanese encephalitis vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  4. Medicines for COVID-19 Informations générales
    Section
    Medicines for COVID-19
    • Refer to WHO living guidelines
    Indications
    COVID-19
  5. Abacavir Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  6. Abacavir + dolutegravir + lamivudine Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  7. Abacavir + lamivudine Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  8. Abacavir + lamivudine + lopinavir + ritonavir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  9. Abemaciclib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast
  10. Abiraterone Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  11. Acamprosate calcium Informations générales
    Section
    Medicines for alcohol use disorders
    • Oral > Solid > tablet: 333 mg
    Indications
    Disorders due to use of alcohol
  12. Acenocoumarol Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to warfarin pour Other specified diseases of arteries or arterioles Therapeutic equivalent to warfarin pour Venous thromboembolism Therapeutic equivalent to warfarin pour Cerebral ischaemic stroke due to embolic occlusion Therapeutic equivalent to warfarin pour Atrial fibrillation
  13. Acetazolamide Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Oral > Solid: 250 mg
    Indications
    Primary open-angle glaucoma
  14. Acetic acid Informations générales
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 2% solution
    Indications
    Infectious diseases of external ear
  15. Acetylcysteine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
    • Oral > Liquid: 10%; 20%
    Indications
    Acute or subacute hepatic failure Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs
  16. Acetylsalicylic acid Informations générales
    Section
    Anti-platelet medicines
    • Oral > Solid: 100 mg
    Indications
    Acute myocardial infarction Cerebral ischaemic stroke
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
    Pain
    Section
    Medicines for acute migraine attacks
    • Oral > Solid: 300 to 500 mg
    Indications
    Migraine
    Section
    Medicines for juvenile joint diseases
    • Local > Rectal > Suppository: 150 mg; 300 mg
    • Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg
    • Oral > Solid > tablet: 75 to 500 mg
    Indications
    Acute rheumatic fever without mention of heart involvement Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis
  17. Acetylsalicylic acid + atorvastatin + ramipril Informations générales
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  18. Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide Informations générales
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  19. Aciclovir Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 3% w/w
    Indications
    Herpes simplex keratitis
    Section
    Antiherpes medicines
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    Indications
    Herpes simplex infections Zoster Varicella
    Section
    Medicines for viral central nervous system infections
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    Indications
    Herpes simplex infections Zoster Varicella
  20. Aclidinium Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease
  21. Activated charcoal Informations générales
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Liquid: 50 mg granules for oral suspension
    Indications
    Unspecified injury, poisoning or certain other consequences of external causes
  22. Adalimumab Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.
    Indications
    Psoriasis of unspecified type
  23. Afatinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung
  24. Albendazole Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    Indications
    Echinococcosis Enterobiasis Trichuriasis Hookworm diseases Cysticercosis Ascariasis
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)
    Indications
    Other specified echinococcosis Cysticercosis of central nervous system
    Section
    Antifilarials
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    Indications
    Lymphatic filariasis
  25. Alcohol based hand rub Informations générales
    Section
    Disinfectants
    • Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
    Indications
    Denatured alcohol
  26. Alcuronium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)
    Indications
    Muscle relaxants
  27. Alfacalcidol Informations générales
    Section
    Medicines for endocrine disorders
    • Oral > Liquid: 2 µg per mL
    • Oral > Solid > capsule: 0.25 µg; 1 µg
    Indications
    Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport
  28. All-trans retinoic acid Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  29. Allopurinol Informations générales
    Section
    Medicines used to treat gout
    • Oral > Solid: 100 mg
    Indications
    Gout
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 500 mg (as sodium) powder for injection
    • Oral > Solid: 100 mg; 300 mg
    Indications
    Tumour lysis syndrome
  30. Alprostadil (prostaglandin E1) Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 0.5 mg per mL in alcohol
    Indications
    Other specified congenital anomaly of great arteries including arterial duct
  31. Alteplase Informations générales
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
    Indications
    Cerebral ischaemic stroke
  32. Amidotrizoate Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
    Indications
    Amidotrizoate
  33. Amikacin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Premier choix
    Neutropenia (high-risk) co-prescrite avec cefotaxime Inflammatory and other diseases of prostate (severe) co-prescrite avec cefotaxime Acute pyelonephritis (severe) co-prescrite avec ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescrite avec ceftriaxone Acute pyelonephritis (severe)
    Second choix
    co-prescrite avec cloxacillin Sepsis without septic shock
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  34. Amiloride Informations générales
    Section
    Diuretics
    • Oral > Solid: 5 mg (hydrochloride)
    Indications
    Oedema Ascites
  35. Amiodarone Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Cardiac arrhythmia
  36. Amitriptyline Informations générales
    Section
    Medicines for depressive disorders
    • Oral > Solid: 25 mg; 75 mg
    Indications
    Depressive disorders
    Section
    Medicines for migraine prophylaxis
    • Oral > Solid > tablet: 25 mg
    Indications
    Migraine
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 25 mg per 5 mL
    • Oral > Solid > tablet: 25 mg; 10 mg; 75 mg
    Indications
    Palliative care
  37. Amlodipine Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 5 mg (as maleate, mesylate or besylate)
    Indications
    Essential hypertension
  38. Amodiaquine Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  39. Amodiaquine - sulfadoxine + pyrimethamine Informations générales
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package
    Indications
    Malaria
  40. Amoxicillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)
    Indications
    Premier choix
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation Periapical abscess without sinus Acute otitis media Acute sinusitis co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec gentamicin Sepsis without septic shock
    Second choix
    Bacterial meningitis
    Autres indications
    Infectious cystitis Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    Indications
    Second choix
    Bacterial meningitis
  41. Amoxicillin + clavulanic acid Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Premier choix
    Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation Peritonitis (mild-moderate) Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choix
    Osteomyelitis or osteitis Acute otitis media Other specified prophylactic measures Bacterial infection of joint Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe)
    Autres indications
    Bacterial infection of unspecified site
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  42. Amphotericin B Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Indications
    Blastomycosis Cryptococcosis Candidosis Coccidioidomycosis Histoplasmosis Sporotrichosis Aspergillosis
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Indications
    Visceral leishmaniasis
  43. Ampicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
    • Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    Premier choix
    co-prescrite avec gentamicin Peritoneal abscess (severe) co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Peritoneal abscess (mild-moderate) co-prescrite avec gentamicin Peritonitis (severe) co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Peritonitis (mild-moderate) co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choix
    Bacterial meningitis
    Autres indications
    Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    Indications
    Second choix
    Bacterial meningitis
  44. Anakinra Informations générales
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe
    Indications
    Juvenile systemic arthritis
  45. Anastrozole Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  46. Anidulafungin Informations générales
    Section
    Antifungal medicines
    Indications
    Therapeutic equivalent to micafungin pour Systemic or invasive candidosis
  47. Ansuvimab Informations générales
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 400 mg powder for injection
    Indications
    Ebola virus disease
  48. Anti-D immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
    Indications
    Rh incompatibility reaction Maternal care for red cell antibodies
  49. Anti-rabies immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
    Rabies
  50. Anti-rabies virus monoclonal antibodies Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
    Indications
    Rabies
  51. Anti-tetanus immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
    Tetanus
  52. Antirabies hyperimmune serum Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule
    Indications
    Rabies
  53. Antivenom immunoglobulin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  54. Antivenom sera Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  55. Apixaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  56. Aprepitant Informations générales
    Section
    Antiemetic medicines
    • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
    • Oral > Solid > capsule: 80 mg; 125 mg; 165 mg
    Indications
    Nausea or vomiting
  57. Aripiprazole Informations générales
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 300 mg powder and solvent for suspension; 400 mg powder and solvent for suspension
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone pour Schizophrenia or other primary psychotic disorders
  58. Arpraziquantel Informations générales
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > dispersible tablet: 150 mg
    Indications
    Therapeutic equivalent to praziquantel pour Schistosomiasis
  59. Arsenic trioxide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  60. Artemether Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL ampoule (oily injection)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  61. Artemether + lumefantrine Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > dispersible tablet: 20 mg + 120 mg
    • Oral > Solid > tablet: 20 mg + 120 mg
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  62. Artesunate Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 30 mg in vial powder for injection; 120 mg in vial powder for injection
    • Local > Rectal > Other: 100 mg capsules
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  63. Artesunate + amodiaquine Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg
    • Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  64. Artesunate + mefloquine Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride); 100 mg + 200 mg (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  65. Artesunate + pyronaridine Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 60 mg + 180 mg (tetraphosphate)
    • Oral > Solid > granules: 20 mg + 60 mg (tetraphosphate)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  66. Artesunate - sulfadoxine + pyrimethamine Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  67. Ascorbic acid Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Scurvy
  68. Asparaginase Informations générales
    Section
    Cytotoxic medicines
    • Powder for injection: 10 000 IU in vial.
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified
  69. Atazanavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  70. Atazanavir + ritonavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  71. Atenolol Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 50 mg; 100 mg
    Indications
    Angina pectoris
    Section
    Antihypertensive medicines
    • Oral > Solid: 50 mg; 100 mg
    Indications
    Essential hypertension Therapeutic equivalent to bisoprolol pour Essential hypertension
  72. Atezolizumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
    • Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab pour Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab pour Adenocarcinoma of stomach Hepatocellular carcinoma of liver
  73. Atoltivimab + maftivimab + odesivimab Informations générales
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
    Indications
    Ebola virus disease
  74. Atorvastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  75. Atorvastatin + perindopril + amlodipine Informations générales
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg
    Indications
    Chronic ischaemic heart disease Atherosclerotic chronic arterial occlusive disease Cerebral ischaemic stroke
  76. Atracurium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL (besylate)
    Indications
    Muscle relaxants Therapeutic equivalent to vecuronium pour Muscle relaxants
  77. Atropine Informations générales
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide pour Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
    Indications
    Anterior uveitis
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate); 400 µg per mL in 1 mL ampoule or vial (sulfate)
    Indications
    Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate)
    Indications
    Exposure to or harmful effects of undetermined intent of pesticides
  78. Axicabtagene ciloleucel Informations générales
    Section
    Antineoplastics and supportive medicines
    • Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.
    Indications
    Diffuse large B-cell lymphomas
  79. Axitinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid > tablet: 1 mg; 3 mg; 5 mg
    Indications
    Renal cell carcinoma of kidney, except renal pelvis
  80. Azacitidine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
    Myeloid leukaemia
  81. Azathioprine Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid > tablet: 25 mg; 50 mg (scored)
    • Oral > Solid > tablet: 50 mg (scored)
    Indications
    Failure or rejection of transplanted organs or tissues Relapsing-remitting multiple sclerosis
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid > tablet: 50 mg (scored)
    Indications
    Rheumatoid arthritis, serology unspecified Psoriatic arthritis
  82. Azithromycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
    Indications
    Trachoma
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    Premier choix
    Chlamydia trachomatis Typhoid fever Yaws Paratyphoid fever Cholera Cholera [children] Trachoma co-prescrite avec ceftriaxone Gonococcal infection
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec cefixime Gonococcal infection
  83. Aztreonam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Other specified bacterial diseases
  84. Baclofen Informations générales
    Section
    Medicines for cerebral palsy
    • Oral > Liquid: 10 mg per 5 mL
    • Parenteral > Locoregional injections > Intrathecal: 500 µg per mL in ampoule
    • Oral > Solid > tablet: 10 mg
    Indications
    Spastic cerebral palsy
  85. Barium sulfate Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Oral > Liquid: Aqueous suspension
    Indications
    Barium sulfate with suspending agents
  86. Beclometasone Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)
    Indications
    Asthma Therapeutic equivalent to budesonide pour Asthma
  87. Beclometasone + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  88. Bedaquiline Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 100 mg tablet; 20 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  89. Beinaglutide Informations générales
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide pour Obesity
  90. Bendamustine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  91. Benzathine benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection
    Indications
    Premier choix
    Syphilis Congenital syphilis [children]
    Autres indications
    Bacterial infection of unspecified site
  92. Benznidazole Informations générales
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg
    Indications
    Chagas disease
  93. Benzoic acid + salicylic acid Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 6% + 3%
    • Local > Topical > Ointment: 6% + 3%
    Indications
    Fungal infection of the skin
  94. Benzoyl peroxide Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 5%
    • Local > Topical > Lotion: 5%
    Indications
    Acne
  95. Benzyl benzoate Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 25%
    Indications
    Pthiriasis Pediculosis corporis Pediculosis capitis Scabies
  96. Benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)
    Indications
    Premier choix
    Congenital syphilis [children] Syphilis co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choix
    Bacterial meningitis
    Autres indications
    Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    Indications
    Second choix
    Bacterial meningitis
  97. Beractant Informations générales
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 25 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  98. Betamethasone Informations générales
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 0.1% (as valerate)
    • Local > Topical > Ointment: 0.1% (as valerate)
    Indications
    Pruritus due to skin disorder Psoriasis of unspecified type Dermatitis or eczema Lichen planus
  99. Bevacizumab Informations générales
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
    Indications
    Age related macular degeneration
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion
    Indications
    Hepatocellular carcinoma of liver
  100. Bicalutamide Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  101. Binimetinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib pour Other specified melanoma of skin
  102. Biperiden Informations générales
    Section
    Medicines for parkinsonism
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
    • Oral > Solid: 2 mg tablet (hydrochloride)
    Indications
    Parkinson disease
  103. Bisacodyl Informations générales
    Section
    Laxatives
    Indications
    Therapeutic equivalent to senna pour Constipation
  104. Bisoprolol Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Angina pectoris
    Section
    Medicines used in heart failure
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Heart failure
    Section
    Antihypertensive medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Essential hypertension
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Cardiac arrhythmia
    Section
    Medicines for migraine prophylaxis
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Migraine
  106. Blinatumomab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial
    Indications
    B lymphoblastic leukaemia or lymphoma, not elsewhere classified
  107. Bortezomib Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  108. Brexpiprazole Informations générales
    Section
    Medicines for depressive disorders
    • Oral > Solid > tablet: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg
    Indications
    Depressive disorders
  109. Bromocriptine Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 2.5 mg; 5 mg
    Indications
    Parkinson disease
    Section
    Medicines for disorders of the pituitary hormone system
    Indications
    Therapeutic equivalent to cabergoline pour Other specified benign neoplasm of endocrine glands
  110. Budesonide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > powder: 100 µg per actuation in dry powder inhaler; 200 µg per actuation in dry powder inhaler
    • Respiratory > Inhalation > suspension: 100 µg per actuation in pressurized metered dose inhaler; 200 µg per actuation in pressurized metered dose inhaler
    Indications
    Asthma
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 32 µg per actuation; 64 µg per actuation
    Indications
    Allergic rhinitis
  111. Budesonide + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > powder: 100 µg + 6 µg per dose actuation in dry powder inhaler; 200 µg + 6 µg per dose actuation in dry powder inhaler
    Indications
    Asthma
  112. Budesonide + salmeterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  113. Bumetanide Informations générales
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide pour Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide pour Anuria or oliguria Therapeutic equivalent to furosemide pour Oedema
  114. Bupivacaine Informations générales
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 8% glucose solution
    • Parenteral > General injections > unspecified: 0.25% (hydrochloride); 0.5% (hydrochloride)
    Indications
    Local anaesthetics
  115. Buprenorphine Informations générales
    Section
    Medicines for opioid use disorders
    Indications
    Therapeutic equivalent to methadone pour Opioid dependence
  116. Bupropion Informations générales
    Section
    Medicines for nicotine use disorders
    • Oral > Solid: 150 mg sustained-release (hydrochloride)
    Indications
    Nicotine dependence
  117. C1 esterase inhibitor Informations générales
    Section
    Plasma-derived medicines
    • Parenteral > General injections > IV: 500 IU in vial powder for injection
    Indications
    Hereditary angioedema
  118. Cabergoline Informations générales
    Section
    Medicines for disorders of the pituitary hormone system
    • Oral > Solid > tablet: 0.5 mg; 1 mg
    Indications
    Other specified benign neoplasm of endocrine glands
    Section
    Antiseizure medicines
    • Oral > Solid > tablet: 0.5 mg
    Indications
    Parkinson disease
  119. Caffeine citrate Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    • Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    Indications
    Apnoea of newborn
  120. Calamine Informations générales
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Lotion:
    Indications
    Pruritus
  121. Calcipotriol Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 50 µg per mL (0.005%)
    • Local > Topical > Lotion: 50 µg per mL (0.005%)
    • Local > Topical > Ointment: 50 µg per mL (0.005%)
    Indications
    Psoriasis of unspecified type
  122. Calcitriol Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to calcipotriol pour Psoriasis of unspecified type
    Section
    Medicines for endocrine disorders
    • Oral > Solid > capsule: 0.25 µg; 0.5 µg
    Indications
    Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport
  123. Calcium Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 500 mg (elemental calcium)
    Indications
    Calcium deficiency
  124. Calcium folinate (leucovorin calcium) Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 15 mg tablet
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant trophoblastic neoplasms of placenta Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon Burkitt lymphoma including Burkitt leukaemia Malignant neoplasm metastasis in large intestine
  125. Calcium gluconate Informations générales
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Tetany due to acute calcium deficiency
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule or vial (10%)
    Indications
    Hypermagnesaemia
  126. Canagliflozin Informations générales
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus
  128. Capreomycin Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  129. Captopril Informations générales
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg
    Indications
    Heart failure
  130. Carbachol Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    Indications
    Therapeutic equivalent to pilocarpine pour Acute angle closure with pupillary block Therapeutic equivalent to pilocarpine pour Ocular hypertension Therapeutic equivalent to pilocarpine pour Primary open-angle glaucoma
  131. Carbamazepine Informations générales
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg
    Indications
    Bipolar or related disorders
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
    Indications
    Epilepsy or seizures
    Section
    Medicines for neurological disorders
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
    • Oral > Solid > capsule: 100 mg (extended-release); 200 mg (extended-release); 300 mg (extended-release)
    Indications
    Trigeminal neuralgia
  132. Carbetocin Informations générales
    Section
    Uterotonics
    • Parenteral > General injections > IV: 100 µg per mL (heat stable)
    Indications
    Postpartum haemorrhage
  133. Carbimazole Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole pour Thyrotoxicosis
  134. Carboplatin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
    Indications
    Other specified gliomas of brain Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Malignant neoplasms of cervix uteri
  135. Carmellose Informations générales
    Section
    Ophthalmological preparations
    Indications
    Therapeutic equivalent to hypromellose pour Keratoconjunctivitis sicca
  136. Carvedilol Informations générales
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol pour Heart failure
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Essential hypertension
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Cardiac arrhythmia
  137. Caspofungin Informations générales
    Section
    Antifungal medicines
    Indications
    Therapeutic equivalent to micafungin pour Systemic or invasive candidosis
  138. Cefalexin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate)
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
    • Oral > Solid > dispersible tablet: 125 mg; 250 mg
    Indications
    Premier choix
    Bacterial cellulitis, erysipelas or lymphangitis
    Second choix
    Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation
    Autres indications
    Bacterial infection of unspecified site
  139. Cefazolin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    Premier choix
    Other specified prophylactic measures co-prescrite avec metronidazole Other specified prophylactic measures
    Second choix
    Osteomyelitis or osteitis Bacterial infection of joint
    Autres indications
    Surgical site infection
  140. Cefepime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection
    Indications
    Other specified bacterial diseases
  141. Cefiderocol Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  142. Cefixime Informations générales
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
    Indications
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec azithromycin Gonococcal infection
  143. Cefotaxime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    Premier choix
    Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate)
    Second choix
    Osteomyelitis or osteitis Bacterial infection of joint Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Sepsis without septic shock
    Autres indications
    Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    Premier choix
    Bacterial meningitis
  144. Ceftaroline Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection
    Indications
    Other specified bacterial diseases
  145. Ceftazidime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    Premier choix
    co-prescrite avec vancomycin Endophthalmitis
    Autres indications
    Pseudomonas aeruginosa resistant to other antibiotic
  146. Ceftazidime + avibactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  147. Ceftolozane + tazobactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa
  148. Ceftriaxone Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    Indications
    Premier choix
    Typhoid fever Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Paratyphoid fever Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec azithromycin Gonococcal infection co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Necrotising fasciitis co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec vancomycin Endophthalmitis
    Second choix
    Bacterial infection of joint Osteomyelitis or osteitis Infectious gastroenteritis or colitis without specification of infectious agent Sepsis without septic shock Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate)
    Autres indications
    Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    Premier choix
    Bacterial meningitis
  149. Cefuroxime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choix
    Other specified prophylactic measures
  150. Cemiplimab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab pour Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab pour Adenocarcinoma of stomach Other specified malignant neoplasms of bronchus or lung
  151. Certolizumab pegol Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to adalimumab pour Psoriasis of unspecified type
  152. Cetirizine Informations générales
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type
  154. Chloramphenicol Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    • Oral > Liquid: 150 mg per 5 mL (as palmitate)
    • Oral > Solid: 250 mg capsule
    Indications
    Second choix
    Bacterial meningitis
    Autres indications
    Bacterial infection of unspecified site
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    Indications
    Second choix
    Bacterial meningitis
  155. Chlorhexidine Informations générales
    Section
    Medicines administered to the neonate [c]
    • Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    • Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    Indications
    Omphalitis of newborn
    Section
    Antiseptics
    • Local > Topical > Solution: 5% (digluconate) for dilution
    Indications
    Chlorhexidine
  156. Chlorine base compound Informations générales
    Section
    Disinfectants
    • Local > Topical > Powder: 0.1% available chlorine for solution
    • Local > Topical > Liquid: 0.1% available chlorine for solution
    • Local > Topical > Solid: 0.1% available chlorine for solution
    Indications
    Disinfectant, not elsewhere classified
  157. Chloroquine Informations générales
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
    Indications
    Rheumatoid arthritis
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Liquid: 50 mg per 5 mL (base)
    • Oral > Solid > tablet: 150 mg (base)
    Indications
    Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate)
    Indications
    Malaria due to Plasmodium ovale Malaria due to Plasmodium malariae Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > Medicines for chemoprophylaxis in travellers
    • Oral > Liquid: 50 mg per 5 mL (base)
    • Oral > Solid > tablet: 150 mg (base)
    Indications
    Malaria due to Plasmodium vivax
  158. Chlorothiazide Informations générales
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Heart failure
  159. Chloroxylenol Informations générales
    Section
    Disinfectants
    • Local > Topical > Solution: 4.8%
    Indications
    Phenol disinfectant, not elsewhere classified
  160. Chlorpromazine Informations générales
    Section
    Medicines for psychotic disorders
    • Oral > Liquid: 25 mg per 5 mL (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Therapeutic equivalent to haloperidol pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  161. Chlortalidone Informations générales
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Heart failure
  162. Chlortetracycline Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma
  163. Cholera vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against cholera alone
  164. Ciclesonide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  165. Ciclopirox Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Solution: 80 mg per g (as hydroxypropyl chitosan)
    Indications
    Onychomycosis
  166. Ciclosporin Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > capsule: 25 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  167. Cimetidine Informations générales
    Section
    Antiulcer medicines
    • Oral > Solid: 200 mg
    • Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule
    Indications
    Peptic ulcer, site unspecified Gastro-oesophageal reflux disease
  168. Ciprofloxacin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid: 250 mg (as hydrochloride)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    Indications
    Premier choix
    Neutropenia (low-risk) Inflammatory and other diseases of prostate (mild to moderate) Typhoid fever Paratyphoid fever Infectious gastroenteritis or colitis without specification of infectious agent Acute pyelonephritis (mild to moderate)
    Second choix
    Cholera Cholera [children] co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritonitis (mild-moderate)
    Autres indications
    Bacterial infection of unspecified site
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 0.3% (as hydrochloride)
    Indications
    Infectious diseases of external ear
  169. Cisplatin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
    • Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Malignant neoplasms of cervix uteri
  170. Cladribine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial
    Indications
    Langerhans cell histiocytosis
    Section
    Medicines for multiple sclerosis
    • Oral > Solid > tablet: 10 mg
    Indications
    Multiple sclerosis
  171. Clarithromycin Informations générales
    Section
    Watch group antibiotics
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Oral > Solid > dosage form: 500 mg; 250 mg
    • Oral > Solid > dosage form: 500 mg
    Indications
    Premier choix
    co-prescrite avec cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)
    Second choix
    Acute pharyngitis co-prescrite avec amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)
    Autres indications
    Helicobacter pylori associated gastric ulcer
  172. Clindamycin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride) capsule
    • Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
    • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
    • Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    Indications
    Premier choix
    co-prescrite avec piperacillin + tazobactam Necrotising fasciitis
    Second choix
    Osteomyelitis or osteitis Bacterial infection of joint
    Autres indications
    Bacterial infection of unspecified site
  173. Clofazimine Informations générales
    Section
    Antileprosy medicines
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Leprosy
    Section
    Antituberculosis medicines
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  174. Clomifene Informations générales
    Section
    Ovulation inducers
    • Oral > Solid: 50 mg (citrate)
    Indications
    Female infertility without specification whether primary or secondary
  175. Clomipramine Informations générales
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Obsessive-compulsive disorder
  176. Clonazepam Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 500 µg
    Indications
    Generalised myoclonic seizure
  177. Clopidogrel Informations générales
    Section
    Anti-platelet medicines
    • Oral > Solid: 75 mg; 300 mg
    Indications
    Acute ischaemic heart disease Presence of coronary angioplasty implant or graft
  178. Clotrimazole Informations générales
    Section
    Antifungal medicines
    • Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
    Indications
    Vulvovaginal candidosis
  179. Cloxacillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
    • Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
    Indications
    Premier choix
    Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitis
    Second choix
    co-prescrite avec amikacin Sepsis without septic shock
    Autres indications
    Bacterial infection of unspecified site
  180. Clozapine Informations générales
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  182. Coagulation factor IX, plasma-derived Informations générales
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B
  183. Coagulation factor IX, recombinant Informations générales
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection
    Indications
    Haemophilia B
  184. Coagulation factor VIII, plasma-derived Informations générales
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Haemophilia A
  185. Coagulation factor VIII, recombinant Informations générales
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection
    Indications
    Haemophilia A
  186. Coal tar Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Psoriasis of unspecified type
  187. Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  188. Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  189. Cobimetinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib pour Other specified melanoma of skin
  190. Codeine Informations générales
    Section
    Opioid analgesics
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
    Pain
    Section
    Antitussives
    • Oral > Solid: 10 mg tablet (codeine phosphate)
    Indications
    Cough
    Section
    Medicines for diarrhoea
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
    Diarrhoea
  191. Colchicine Informations générales
    Section
    Medicines used to treat gout
    • Oral > Solid: 0.5 mg
    Indications
    Gout
  192. Colecalciferol Informations générales
    Section
    Vitamins and minerals
    • Oral > Liquid: 400 IU per mL
    • Oral > Solid: 400 IU; 1000 IU
    Indications
    Calcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Calcium deficiency
  193. Colistin (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
    Indications
    Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  194. Compound sodium lactate solution Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: injectable solution
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance Hypovolaemic shock
  196. Copper-containing intrauterine device Informations générales
    Section
    Intrauterine devices
    • -
    Indications
    Contact with health services for insertion of contraceptive device
  197. Crizotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 200 mg; 250 mg
    • Oral > Solid > capsule: 200 mg; 250 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Anaplastic large cell lymphoma, ALK-positive
  199. Cryoprecipitate (pathogen-reduced) Informations générales
    Section
    Blood and blood components
    • Injection: frozen liquid in bag or lyophilized powder in vial containing:
    • > 50 IU Factor VIII
    • > 100 IU vWF
    • > 140 mg clottable fibrinogen per unit
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage Haemophilia A Von Willebrand disease
  200. Cyanocobalamin Informations générales
    Section
    Antianaemia medicines
    • .
    Indications
    Anaemias or other erythrocyte disorders
  201. Cyclizine Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 50 mg per mL (lactate)
    • Oral > Solid > tablet: 50 mg (hydrochloride)
    Indications
    Palliative care
  202. Cyclopentolate Informations générales
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide pour Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    Indications
    Therapeutic equivalent to atropine pour Anterior uveitis
  203. Cyclophosphamide Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 25 mg tablet
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid > dosage form: 25 mg; 50 mg
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Rhabdomyosarcoma primary site Hodgkin lymphoma Plasma cell myeloma Other specified gliomas of brain Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  204. Cycloserine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dosage form: 250 mg; 125 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  206. Cytisine (cytisinicline) Informations générales
    Section
    Medicines for nicotine use disorders
    • Oral > Solid > tablet: 1.5 mg
    Indications
    Nicotine dependence
  207. Dabigatran Informations générales
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
    Indications
    Venous thromboembolism Other specified atrial fibrillation
  208. Dabrafenib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 50 mg; 75 mg
    Indications
    Other specified melanoma of skin
  209. Dacarbazine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  210. Daclatasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)
    Indications
    Chronic hepatitis C
  211. Daclatasvir + sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg
    Indications
    Chronic hepatitis C
  213. Dalteparin Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism
  214. Dapagliflozin Informations générales
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus
  215. Dapsone Informations générales
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
    Leprosy
  216. Daptomycin Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection
    Indications
    Other specified bacterial diseases
  217. Daratumumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL
    Indications
    Plasma cell myeloma
  218. Darbepoetin alfa Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Drug-induced aplastic anaemia
  219. Darunavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  220. Dasabuvir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 250 mg tablet
    Indications
    Chronic hepatitis C
  221. Dasatinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  222. Daunorubicin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
    Indications
    Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Myeloid leukaemia
  223. Deferasirox Informations générales
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias Therapeutic equivalent to deferoxamine pour Thalassaemias
  224. Deferiprone Informations générales
    Section
    Other medicines for haemoglobinopathies
    Indications
    Therapeutic equivalent to deferasirox pour Other specified sickle cell disorders or other haemoglobinopathies Therapeutic equivalent to deferasirox pour Thalassaemias
  225. Deferoxamine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Harmful effects of drugs, medicaments or biological substances, not elsewhere classified
    Section
    Other medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias
  226. Delafloxacin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 300 mg lyophilized powder for injection
    • Oral > Solid: 450 mg
    Indications
    Methicillin resistant Staphylococcus aureus
  227. Delamanid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 25 mg
    • Oral > Solid > tablet: 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  228. Dengue vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  229. Desmopressin Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 150 µg per actuation (acetate)
    Indications
    Haemophilia A Von Willebrand disease
  230. Dexamethasone Informations générales
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
    Indications
    Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy
    Section
    Hormones and antihormones
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base
    • Oral > Solid > tablet: 4 mg (as dexamethasone base)
    • Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
    Indications
    Anaplastic large cell lymphoma, ALK-negative Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-positive
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL (as sodium phosphate); 0.5 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (dexamethasone phosphate (as sodium phosphate) equialent to 3.3 mg dexamethasone base)
    • Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base); 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base)
    Indications
    Palliative care
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Antiemetic medicines
    • Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 4 mg (as dexamethasone base); 2 mg (as dexamethasone base)
    Indications
    Nausea or vomiting
  231. Dextran 40 Informations générales
    Section
    Plasma substitutes
    • .
    Indications
    Hypovolaemia
  232. Dextran 70 Informations générales
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 6% injectable solution
    Indications
    Hypovolaemia
  234. Diazepam Informations générales
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 5 mg (scored); 2 mg (scored)
    Indications
    Anxiety
    Section
    Antiseizure medicines
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    Indications
    Therapeutic equivalent to lorazepam pour Status epilepticus Status epilepticus
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    • Parenteral > General injections > unspecified: 5 mg per mL
    • Oral > Solid > tablet: 5 mg (scored); 10 mg (scored); 2 mg (scored)
    Indications
    Palliative care
  235. Diazoxide Informations générales
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
    Indications
    Persistent hyperinsulinaemic hypoglycaemia of infancy
  236. Didanosine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
    • Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  237. Diethylcarbamazine Informations générales
    Section
    Antifilarials
    • Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
    Indications
    Lymphatic filariasis
  238. Digitoxin Informations générales
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule
    • Oral > Solid: 50 µg; 100 µg
    Indications
    Heart failure
  239. Digoxin Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Indications
    Cardiac arrhythmia
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg
    Indications
    Heart failure
  240. Dihydroartemisinin + piperaquine Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate); 40 mg + 320 mg (phosphate)
    • Oral > Solid > tablet: 40 mg + 320 mg (phosphate); 20 mg + 160 mg (phosphate); 60 mg + 480 (phosphate); 80 mg + 640 mg (phosphate)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  241. Dihydroergocryptine mesylate Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid:
    Indications
    Parkinson disease
  242. Diloxanide Informations générales
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Solid: 500 mg (furoate)
    Indications
    Amoebiasis
  243. Dimercaprol Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule; 100 mg per mL in 3 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  244. Dinoprostone (prostaglandin E2) Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 1 mg per mL
    Indications
    Other specified congenital anomaly of great arteries including arterial duct Therapeutic equivalent to alprostadil (prostaglandin E1) pour Other specified congenital anomaly of great arteries including arterial duct
  245. Diphtheria antitoxin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
    Indications
    Need for immunization against diphtheria alone
  246. Diphtheria vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria alone
  247. Diphtheria-pertussis-tetanus vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria-tetanus-pertussis, combined
  248. Diphtheria-tetanus vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against combinations of infectious diseases
  250. Docusate sodium Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 50 mg per 5 mL; 12.5 mg per 5 mL
    • Oral > Solid > capsule: 100 mg
    Indications
    Palliative care
  251. Dolasetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  252. Dolutegravir Informations générales
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  253. Dolutegravir + lamivudine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  254. Donepezil Informations générales
    Section
    Medicines for diseases of the nervous system
    • Oral > Liquid: 1 mg per mL (hydrochloride)
    • Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)
    Indications
    Dementia due to Alzheimer disease
  255. Dopamine Informations générales
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
    Indications
    Heart failure Cardiogenic shock
  256. Dostarlimab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of corpus uteri
  257. Doxorubicin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Rhabdomyosarcoma primary site Malignant neoplasms of breast Hodgkin lymphoma Plasma cell myeloma Follicular lymphoma Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-positive Ewing sarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphoma, not otherwise specified
  258. Doxorubicin (as pegylated liposomal) Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Kaposi sarcoma of unspecified primary site
  259. Doxycycline Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
    • Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    • Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
    • Oral > Solid > dosage form: 100 mg (as hyclate)
    Indications
    Premier choix
    Chlamydia trachomatis Cholera
    Second choix
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Chronic obstructive pulmonary disease with acute exacerbation Cholera [children]
    Autres indications
    Bacterial infection of unspecified site
    Section
    Antimalarial medicines > Medicines for chemoprophylaxis in travellers
    • Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    • Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid: 100 mg (hydrochloride or hyclate)
    Indications
    Malaria due to Plasmodium falciparum
  260. Dulaglutide Informations générales
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide pour Obesity Therapeutic equivalent to semaglutide pour Type 2 diabetes mellitus
  262. Edoxaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  263. Efavirenz Informations générales
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Solid: 600 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  264. Efavirenz + emtricitabine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  265. Efavirenz + lamivudine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  266. Eflornithine Informations générales
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)
    Indications
    Gambiense trypanosomiasis
  267. Elbasvir + grazoprevir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 50 mg + 100 mg
    Indications
    Chronic hepatitis C
  268. Eletriptan Informations générales
    Section
    Medicines for acute migraine attacks
    • Oral > Solid > tablet: 40 mg
    Indications
    Therapeutic equivalent to sumatriptan pour Migraine
  269. Elexacaftor + tezacaftor + ivacaftor Informations générales
    Section
    Medicines for cystic fibrosis
    • Oral > Solid > tablet: 50 mg + 25 mg + 37.5 mg; 100 mg + 50 mg + 75 mg
    • Oral > Solid > granules: 80 mg + 40 mg + 60 mg in sachet; 100 mg + 50 mg + 75 mg in sachet
    Indications
    Cystic fibrosis
  270. Emicizumab Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial
    Indications
    Haemophilia A
  271. Empagliflozin Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 10 mg; 25 mg
    Indications
    Type 2 diabetes mellitus
  272. Emtricitabine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid: 200 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  273. Emtricitabine + rilpivirine + tenofovir alafenamide Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 25 mg + 25 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  274. Emtricitabine + rilpivirine + tenofovir disoproxil fumarate Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  275. Emtricitabine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
  276. Emtricitabine + tenofovir alafenamide Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  277. Enalapril Informations générales
    Section
    Antihypertensive medicines
    • Oral > Liquid: 1 mg per mL (as hydrogen maleate)
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Heart failure
  278. Encorafenib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin
  279. Enoxaparin Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
    Indications
    Acute ischaemic heart disease Venous thromboembolism
  280. Entecavir Informations générales
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Chronic hepatitis B
  281. Enzalutamide Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 40 mg
    Indications
    Therapeutic equivalent to abiraterone pour Malignant neoplasms of prostate Malignant neoplasms of prostate
  282. Ephedrine Informations générales
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
    Indications
    Cardiac complications of anaesthesia during labour or delivery
  283. Epinephrine Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
    Indications
    Cardiac arrest
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
    Indications
    Primary open-angle glaucoma
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Asthma Chronic obstructive pulmonary disease
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Anaphylaxis
  284. Epoetin alfa Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Drug-induced aplastic anaemia
  285. Epoetin beta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Drug-induced aplastic anaemia
  286. Epoetin theta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  287. Eptinezumab Informations générales
    Section
    Medicines for migraine prophylaxis
    Indications
    Therapeutic equivalent to fremanezumab pour Chronic migraine
  288. Equine rabies immunoglobulin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
    Indications
    Rabies
  289. Eravacycline Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg lyophilized powder for injection
    Indications
    Carbapenem resistant Enterobacterales
  290. Erenumab Informations générales
    Section
    Medicines for migraine prophylaxis
    Indications
    Therapeutic equivalent to fremanezumab pour Chronic migraine
  291. Ergocalciferol Informations générales
    Section
    Vitamins and minerals
    • Oral > Liquid: 250 µg per mL (10 000 IU per mL)
    • Oral > Solid: 1.25 mg (50 000 IU)
    Indications
    Therapeutic equivalent to colecalciferol pour Calcium deficiency Therapeutic equivalent to colecalciferol pour Vitamin D deficiency Vitamin D deficiency Calcium deficiency
  292. Ergometrine Informations générales
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
    Indications
    Postpartum haemorrhage
  293. Erlotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  294. Erythromycin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
    • Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
    • Oral > Solid: 250 mg (as stearate or ethylsuccinate)
    Indications
    Second choix
    Therapeutic equivalent to clarithromycin pour Acute pharyngitis
    Autres indications
    Bacterial infection of unspecified site
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 0.5%
    Indications
    Chlamydial conjunctivitis Gonococcal infection of eye
  295. Erythropoiesis-stimulating agents Informations générales
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
    Section
    Supportive medicines
    • Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)
    Indications
    Drug-induced aplastic anaemia
  296. Estradiol Informations générales
    Section
    Estrogens
    • Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg
    Indications
    Gonadotropin deficiency Hypopituitarism Turner syndrome
  297. Estradiol cypionate + medroxyprogesterone acetate Informations générales
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 5 mg + 25 mg
    Indications
    Contact with health services for reasons associated with reproduction
  298. Etanercept Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to adalimumab pour Psoriasis of unspecified type
  299. Ethambutol Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Other specified tuberculosis Tuberculosis
  300. Ethambutol + isoniazid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  301. Ethambutol + isoniazid + pyrazinamide + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  302. Ethambutol + isoniazid + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
    Tuberculosis
  303. Ethanol Informations générales
    Section
    Antiseptics
    • Local > Topical > Solution: 70% (denatured)
    Indications
    Denatured alcohol
  304. Ether Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > solution:
    Indications
    Anaesthetics and therapeutic gases
  305. Ethinylestradiol + etonogestrel Informations générales
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
    Indications
    Contact with health services for contraceptive management
  306. Ethinylestradiol + levonorgestrel Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 50 µg + 250 µg [4]
    • Oral > Solid: 30 µg + 150 µg
    Indications
    Contact with health services for postcoital contraception Contact with health services for contraceptive management
  307. Ethinylestradiol + norethisterone Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 35 µg + 1 mg
    Indications
    Contact with health services for contraceptive management
  308. Ethionamide Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 125 mg
    • Oral > Solid > tablet: 250 mg
    Indications
    Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis
  309. Ethosuximide Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg
    Indications
    Absence seizures, typical
  310. Etonogestrel-releasing implant Informations générales
    Section
    Implantable contraceptives
    • Implant > Subdermal: 68 mg single rod
    Indications
    Contact with health services for insertion of contraceptive device
  311. Etoposide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
    • Oral > Solid: 100 mg capsule
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
    • Oral > Solid: 100 mg capsule; 50 mg capsule
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Ewing sarcoma of bone and articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Burkitt lymphoma including Burkitt leukaemia
  312. Everolimus Informations générales
    Section
    Targeted therapies
    • Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
    • Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
    Indications
    Other specified gliomas of brain
  313. Exenatide Informations générales
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide pour Obesity
  314. Fentanyl Informations générales
    Section
    Opioid analgesics
    • Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
    • Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)
    • Oral > Other: 200 to 1200 µg buccal film (as citrate)
    Indications
    Chronic cancer pain Other specified chronic cancer related pain
  315. Ferrous salt Informations générales
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron
    • Oral > Solid > tablet: 60 to 65 mg elemental iron
    Indications
    Iron deficiency anaemia
  316. Ferrous salt + folic acid Informations générales
    Section
    Antianaemia medicines
    • Oral > Solid: 60 mg iron + 2.8 mg
    • Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
    Indications
    Iron deficiency anaemia Clefts of lip, alveolus or palate Iron deficiency anaemia Anencephaly or similar anomalies Spina bifida
  317. Fexinidazole Informations générales
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Oral > Solid > tablet: 600 mg
    • Oral > Solid: 600 mg
    Indications
    Rhodesiense trypanosomiasis Gambiense trypanosomiasis
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid > tablet: 600 mg
    • Oral > Solid: 600 mg
    Indications
    Rhodesiense trypanosomiasis Gambiense trypanosomiasis
  318. Fexofenadine Informations générales
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type
  319. Fifth generation cephalosporins Informations générales
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  320. Filgrastim Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  321. Fingolimod Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Oral > Solid: 0.25 mg; 0.5 mg
    Indications
    Relapsing-remitting multiple sclerosis
  322. Flomoxef Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified other antibiotic resistant Enterobacterales
  323. Fluconazole Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2 mg per mL in vial
    • Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
    • Oral > Solid > capsule: 50 mg
    Indications
    Cryptococcosis Candidosis
  324. Flucytosine Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2.5 g per 250 mL infusion
    • Oral > Solid: 250 mg capsule
    Indications
    Cryptococcosis
  325. Fludarabine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  326. Fludrocortisone Informations générales
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Liquid: 100 µg per mL
    • Oral > Solid > tablet: 100 µg (acetate)
    Indications
    Adrenocortical insufficiency
  327. Flunisolide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  328. Fluorescein Informations générales
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
    Indications
    Fluorescein
  329. Fluoride Informations générales
    Section
    Dental medicines and preparations
    • Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
    • Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
    • Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
    • Local > Dental > Varnish: 22500 ppm fluoride (any type)
    Indications
    Dental caries
  330. Fluorouracil Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Ointment: 5%
    Indications
    Plantar warts
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
    • Parenteral > General injections > IV: 50 mg per mL in vial
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of nasopharynx Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of rectum Malignant neoplasms of colon
  331. Fluoxetine Informations générales
    Section
    Medicines for depressive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Depressive disorders
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Palliative care
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Social anxiety disorder Generalised anxiety disorder Panic disorder
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Obsessive-compulsive disorder
  332. Fluphenazine Informations générales
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
    Indications
    Schizophrenia or other primary psychotic disorders
  333. Flutamide Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate
  334. Fluticasone Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  335. Fluticasone + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  336. Fluticasone furoate + vilanterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  337. Fluvastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  338. Folic acid Informations générales
    Section
    Antianaemia medicines
    • Oral > Solid: 400 µg
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    Indications
    Anencephaly or similar anomalies Spina bifida Cephalocele Folate deficiency anaemia
  339. Fomepizole Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule or vial (sulfate); 1 g per mL in 1.5 mL ampoule or vial (base)
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  340. Fosfomycin (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  341. Fourth generation cephalosporins Informations générales
    Section
    Watch group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  342. Fremanezumab Informations générales
    Section
    Medicines for migraine prophylaxis
    • Parenteral > General injections > SC: 225 mg per 1.5 mL in pre-filled syringe
    Indications
    Chronic migraine
  343. Fresh-frozen plasma Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  344. Fulvestrant Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 250 mg per 5 mL
    Indications
    Malignant neoplasms of breast
  345. Furosemide Informations générales
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Anuria or oliguria Oedema
  346. Gabapentin Informations générales
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg
    Indications
    Neuropathic pain
  347. Galcanezumab Informations générales
    Section
    Medicines for migraine prophylaxis
    Indications
    Therapeutic equivalent to fremanezumab pour Chronic migraine
  348. Gallamine Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)
    Indications
    Muscle relaxants
  349. Gatifloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  350. Gefitinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung
  351. Gemcitabine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  352. Gentamicin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    Premier choix
    Neonatal meningitis co-prescrite avec amoxicillin Sepsis without septic shock co-prescrite avec amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Sepsis without septic shock co-prescrite avec ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec ampicillin Peritoneal abscess (severe) co-prescrite avec ampicillin Peritonitis (mild-moderate) co-prescrite avec ampicillin Peritonitis (severe) co-prescrite avec ampicillin Peritoneal abscess (mild-moderate) co-prescrite avec benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Sepsis without septic shock
    Second choix
    Other specified prophylactic measures Gonococcal infection
    Autres indications
    Bacterial infection of unspecified site
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
    Indications
    Other specified conjunctivitis Infectious blepharitis
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    Premier choix
    Neonatal meningitis
  353. Glass ionomer cement Informations générales
    Section
    Dental medicines and preparations
    • Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid
    Indications
    Dental caries
  354. Glatiramer acetate Informations générales
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe
    • Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL
    Indications
    Multiple sclerosis Relapsing-remitting multiple sclerosis
  355. Glecaprevir + pibrentasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 50 mg + 20 mg granules
    • Oral > Solid > tablet: 100 mg + 40 mg
    Indications
    Chronic hepatitis C
  356. Glibenclamide Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 5 mg; 2.5 mg
    Indications
    Type 2 diabetes mellitus
  357. Gliclazide Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
    Indications
    Type 2 diabetes mellitus
  358. Glucagon Informations générales
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent
    Indications
    Hypoglycaemia in the context of diabetes
  359. Glucose Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
    • Parenteral > General injections > IV: 50% hypertonic
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance Hypoglycaemia without associated diabetes
  360. Glucose + sodium chloride Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  361. Glutaral Informations générales
    Section
    Disinfectants
    • Local > Topical > Solution: 2%
    Indications
    Glutaral nonmedicinal
  362. Glycerol Informations générales
    Section
    Dermatological medicines > Moisturizers
    • Local > Topical > Cream: 15 to 20%
    Indications
    Atopic eczema
  363. Glyceryl trinitrate Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 500 µg sublingual tablet
    Indications
    Angina pectoris
  364. Glycopyrronium Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease
  365. Golimumab Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  366. Goserelin Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate
  367. Granisetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  368. Griseofulvin Informations générales
    Section
    Antifungal medicines
    • Oral > Liquid: 125 mg per 5 mL
    • Oral > Solid: 125 mg; 250 mg
    Indications
    Dermatophytosis
  369. Haemophilus influenzae type b vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  370. Haloperidol Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 0.5 mg; 2 mg; 5 mg
    • Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
    Indications
    Palliative care
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 5 mg per mL in ampoule
    • Oral > Solid: 2 mg; 5 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  371. Haloperidol decanoate Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to fluphenazine pour Schizophrenia or other primary psychotic disorders
  372. Halothane Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  373. Heparin sodium Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial
    Indications
    Acute ischaemic heart disease Unstable angina Venous thromboembolism
  374. Hepatitis A vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  375. Hepatitis B vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  376. Hepatitis E vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  377. Homatropine Informations générales
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)
    Indications
    Anterior uveitis Therapeutic equivalent to atropine pour Anterior uveitis
  378. Human papilloma virus (HPV) vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  379. Hydralazine Informations générales
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
    • Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Essential hypertension Gestational hypertension
  380. Hydrochlorothiazide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg; 12.5 mg
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Oral > Solid > dosage form: 25 mg; 12.5 mg
    Indications
    Oedema
  381. Hydrocortisone Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Ointment: 1% (acetate)
    Indications
    Scleritis Anterior uveitis
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
    Indications
    Anaphylaxis
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Suppository: 25 mg (acetate)
    • Local > Rectal > Retention enema: 100 mg per 60 mL
    Indications
    Crohn disease site Ulcerative colitis
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 1% (acetate)
    • Local > Topical > Ointment: 1% (acetate)
    Indications
    Dermatitis or eczema Lichen planus Pruritus due to skin disorder Psoriasis of unspecified type
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 5 mg; 10 mg; 20 mg
    • Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule
    Indications
    Adrenocortical insufficiency
  382. Hydromorphone Informations générales
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine pour Pain
  383. Hydroxocobalamin Informations générales
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
    Indications
    Megaloblastic anaemia due to vitamin B12 deficiency
  384. Hydroxycarbamide (hydroxyurea) Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Indications
    Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies
  385. Hydroxychloroquine Informations générales
    Section
    Antimalarial medicines > For chemoprevention
    Indications
    Therapeutic equivalent to chloroquine pour Malaria due to Plasmodium falciparum
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 200 mg (as sulfate)
    Indications
    Systemic lupus erythematosus Cutaneous lupus erythematosus of unspecified type
  386. Hyoscine butylbromide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 20 mg per mL injection
    Indications
    Palliative care
  387. Hyoscine hydrobromide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
    • Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
    Indications
    Palliative care
  388. Hypochlorous acid Informations générales
    Section
    Disinfectants
    • Solution (aqueous): containing hypochlorous acid ≥ 150 parts per million
    Indications
    Disinfectant, not elsewhere classified
    Section
    Antiseptics
    • Solution (aqueous): containing hypochlorous acid ≥ 150 parts per million
    Indications
    Hypochlorite
  389. Hypromellose Informations générales
    Section
    Ophthalmological preparations
    • Local > Ophthalmological > Solution (eye drops): 0.3%
    Indications
    Keratoconjunctivitis sicca
  390. Ibrutinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  391. Ibuprofen Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 5 mg per mL
    Indications
    Patent arterial duct
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg; 600 mg
    Indications
    Pain
    Section
    Medicines for acute migraine attacks
    • Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg
    Indications
    Migraine
  392. Idoxuridine Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.1%
    • Local > Ophthalmological > Ointment: 0.2%
    Indications
    Herpes simplex keratitis
  393. Ifosfamide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Burkitt lymphoma including Burkitt leukaemia
  395. Imipenem + cilastatin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
    Indications
    Second choix
    Therapeutic equivalent to meropenem pour Neutropenia (high-risk) Therapeutic equivalent to meropenem pour Peritoneal abscess (severe) Therapeutic equivalent to meropenem pour Peritonitis (severe)
    Autres indications
    Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to meropenem pour Multi-drug resistant Mycobacterium tuberculosis
  396. Imipenem + cilastatin + relebactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
    • Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection
    Indications
    Other specified other antibiotic resistant Enterobacterales Carbapenem resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa
  397. Indapamide Informations générales
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Heart failure
  398. Indinavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 400 mg (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  399. Indometacin Informations générales
    Section
    Medicines administered to the neonate [c]
    Indications
    Therapeutic equivalent to ibuprofen pour Patent arterial duct
  400. Infliximab Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to adalimumab pour Psoriasis of unspecified type
  401. Influenza vaccine (seasonal) Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against influenza
  402. Insulin (analogue, long-acting) Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  403. Insulin (analogue, rapid-acting) Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  404. Insulin (human, intermediate-acting) Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  405. Insulin (human, short-acting) Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  406. Insulin analogues Informations générales
    Section
    Insulins
    • Not specified
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  407. Insulin aspart Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 2 diabetes mellitus
  408. Insulin degludec Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
    Indications
    Therapeutic equivalent to insulin glargine pour Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 1 diabetes mellitus
  409. Insulin detemir Informations générales
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin glargine pour Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 1 diabetes mellitus
  410. Insulin glargine Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
    Indications
    Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) pour Type 1 diabetes mellitus
  411. Insulin glulisine Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 2 diabetes mellitus
  412. Insulin lispro Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) pour Type 2 diabetes mellitus
  413. Intraperitoneal dialysis solution Informations générales
    Section
    Peritoneal dialysis solution
    • Solution: of appropriate composition in accordance with local clinical guidelines.
    Indications
    Care involving peritoneal dialysis
  414. Iodine Informations générales
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to povidone iodine pour Povidone iodine
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 480 mg per mL in 10 mL ampoule or vial iodized oil (oral or injectable)
    Indications
    Iodine deficiency
  415. Iodine + potassium iodide (Lugol's solution) Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 5% w/v + 10% w/v (aqueous)
    Indications
    Thyrotoxicosis
  416. Iohexol Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
    Indications
    X-ray contrast media, iodinated
  417. Ipecacuanha Informations générales
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine
    Indications
    Unspecified injury, poisoning or certain other consequences of external causes
  418. Ipilimumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Melanoma of skin
  419. Ipratropium bromide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > solution: 20 µg per actuation in pressurized metered dose inhaler
    Indications
    Chronic obstructive pulmonary disease Asthma
  420. Irinotecan Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site
  421. Isoflurane Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  422. Isoniazid Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 100 mg per mL
    • Oral > Solid > dispersible tablet: 100 mg (scored)
    • Oral > Solid > tablet: 100 mg; 300 mg
    Indications
    Other specified tuberculosis Tuberculosis
  423. Isoniazid + pyrazinamide + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg
    Indications
    Tuberculosis
  424. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim Informations générales
    Section
    Medicines for prevention of HIV-related opportunistic infections
    • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
    Indications
    Other specified prophylactic measures
  425. Isoniazid + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 75 mg
    • Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg
    Indications
    Tuberculosis
  426. Isoniazid + rifapentine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
    Indications
    Latent tuberculosis
  427. Isoprenaline Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)
    • Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)
    Indications
    Bradycardia Cardiogenic shock
  428. Isosorbide dinitrate Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 5 mg sublingual tablet
    Indications
    Angina pectoris
  430. Ivacaftor Informations générales
    Section
    Medicines for cystic fibrosis
    • Oral > Solid > tablet: 75 mg; 150 mg
    • Oral > Solid > granules: 59.5 mg; 75 mg
    Indications
    Cystic fibrosis
  431. Ivermectin Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 3 mg
    Indications
    Strongyloidiasis Ascariasis Trichuriasis Hookworm diseases Ancylostomiasis
    Section
    Medicines for ectoparasitic infections
    • Oral > Solid > tablet: 3 mg
    Indications
    Scabies
    Section
    Antifilarials
    • Oral > Solid > tablet: 3 mg
    Indications
    Lymphatic filariasis Onchocerciasis
  432. Kanamycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
  433. Kanamycin (injection) Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  434. Ketamine Informations générales
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 10 mg per mL in vial (as hydrochloride); 50 mg per mL in vial (as hydrochloride)
    Indications
    Anaesthetics and therapeutic gases
  435. Ketoconazole Informations générales
    Section
    Medicines for endocrine disorders
    • Oral > Solid > tablet: 200 mg
    Indications
    Cushing syndrome
  436. Lactulose Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 3.3 to 3.4 g per 5 mL oral liquid
    Indications
    Palliative care
  437. Lamivudine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 150 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  438. Lamivudine + nevirapine + zidovudine Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  440. Lamivudine + zidovudine Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  441. Lamotrigine Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
    Indications
    Epilepsy or seizures
  442. Latanoprost Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
    Indications
    Primary open-angle glaucoma
  443. Ledipasvir + sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
    Indications
    Chronic hepatitis C
  444. Lenalidomide Informations générales
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  445. Lenvatinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid > capsule: 4 mg; 10 mg
    Indications
    Renal cell carcinoma of kidney, except renal pelvis
  446. Letrozole Informations générales
    Section
    Ovulation inducers
    • Oral > Solid > dosage form: 2.5 mg
    Indications
    Female infertility without specification whether primary or secondary
  447. Leuprorelin Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of breast Malignant neoplasms of prostate
  448. Levamisole Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)
    Indications
    Ascariasis
  449. Levetiracetam Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
    • Parenteral > General injections > IV: 100 mg per mL in 5 mL ampoule or vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag
    Indications
    Epilepsy or seizures Status epilepticus
  450. Levodopa Informations générales
    Section
    Medicines for parkinsonism
    • Oral > Solid: 250 mg
    Indications
    Parkinson disease
  451. Levodopa + benserazide Informations générales
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to levodopa + carbidopa pour Parkinson disease
  452. Levodopa + carbidopa Informations générales
    Section
    Medicines for parkinsonism
    • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
    Indications
    Parkinson disease
  453. Levofloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  454. Levonorgestrel Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 750 µg [2]; 1.5 mg [1]
    • Oral > Solid: 30 µg
    Indications
    Contact with health services for postcoital contraception Contact with health services for contraceptive management
    Section
    Intrauterine devices
    • Intrauterine system with reservoir containing 52 mg of levonorgestrel.
    Indications
    Contact with health services for insertion of contraceptive device
  455. Levonorgestrel-releasing implant Informations générales
    Section
    Implantable contraceptives
    • Implant > Subdermal: 75 mg per rod (two-rods)
    Indications
    Contact with health services for insertion of contraceptive device
  456. Levothyroxine Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
    Hypothyroidism
  457. Lidocaine Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
    Indications
    Ventricular tachyarrhythmia
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > Locoregional injections > Other: 1% (hydrochloride); 2% (hydrochloride); 0.5% (hydrochloride)
    • Local > Topical > unspecified: 2 to 4% (hydrochloride)
    Indications
    Local anaesthetics
  458. Lidocaine + epinephrine Informations générales
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine
    • Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
    Indications
    Local anaesthetics
  459. Lindane Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Cream: 1%
    • Local > Topical > Lotion: 1%
    Indications
    Scabies
  460. Linezolid Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 400 mg tablet; 600 mg tablet
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
    Indications
    Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg (scored)
    • Oral > Solid > tablet: 600 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  461. Liraglutide Informations générales
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen
    Indications
    Obesity
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide pour Obesity Therapeutic equivalent to semaglutide pour Type 2 diabetes mellitus
  462. Lisinopril + amlodipine Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
    Indications
    Essential hypertension
  463. Lisinopril + hydrochlorothiazide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
    Indications
    Essential hypertension
  464. Lisocabtagene maraleucel Informations générales
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel pour Diffuse large B-cell lymphomas
  465. Lithium carbonate Informations générales
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 300 mg
    Indications
    Bipolar or related disorders
  466. Loperamide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid > dosage form: 2 mg
    Indications
    Palliative care
  467. Lopinavir + ritonavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
    • Oral > Solid > dosage form: 40 mg + 10 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  468. Loratadine Informations générales
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid > tablet: 10 mg; 5 mg (chewable); 10 mg (chewable)
    Indications
    Allergic or hypersensitivity conditions of unspecified type
  469. Lorazepam Informations générales
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to diazepam pour Anxiety
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
    Indications
    Status epilepticus
  470. Losartan Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Heart failure
  471. Lovastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  472. Magnesium sulfate Informations générales
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
    • Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
    Indications
    Severe pre-eclampsia Eclampsia
  473. Malaria vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain specified single infectious diseases
  474. Mannitol Informations générales
    Section
    Diuretics
    • Parenteral > General injections > IV: 10% solution; 20% solution
    Indications
    Ocular hypertension Cerebral oedema
  475. Measles vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against measles alone
  476. Mebendazole Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
    Indications
    Ascariasis Enterobiasis Trichuriasis Hookworm diseases
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
    Indications
    Other specified echinococcosis
  477. Medroxyprogesterone acetate Informations générales
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
    • Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
    Indications
    Contact with health services for reasons associated with reproduction
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle
  478. Mefloquine Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > Medicines for chemoprophylaxis in travellers
    • Oral > Solid > tablet: 250 mg (scored) (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  479. Meglumine antimoniate Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
    Indications
    Visceral leishmaniasis Cutaneous leishmaniasis Mucocutaneous leishmaniasis
  480. Meglumine iotroxate Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
    Indications
    X-ray contrast media, iodinated
  481. Melarsoprol Informations générales
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
    Indications
    Rhodesiense trypanosomiasis Gambiense trypanosomiasis
  482. Melphalan Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  483. Meningococcal meningitis vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  485. Meropenem Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choix
    Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choix
    Neonatal meningitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  486. Meropenem + vaborbactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii
  487. Mesalazine Informations générales
    Section
    Anti-inflammatory medicines
    Indications
    Therapeutic equivalent to sulfasalazine pour Crohn disease site Therapeutic equivalent to sulfasalazine pour Ulcerative colitis
  488. Mesna Informations générales
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
    • Oral > Solid: 400 mg; 600 mg
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
    • Oral > Solid > tablet: 400 mg; 600 mg
    • Oral > Other: 600 mg
    • Oral > Solid > tablet: 400 mg
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified malignant neoplasms of the ovary Osteosarcoma of bone and articular cartilage of other specified sites Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Germ cell tumour of testis
  489. Metformin Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
    Indications
    Type 2 diabetes mellitus
  490. Methadone Informations générales
    Section
    Medicines for opioid use disorders
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    Indications
    Opioid dependence
    Section
    Opioid analgesics
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 25 mg per 5 mL (methadone hydrochloride); 50 mg per 5 mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    • Oral > Solid > tablet: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)
    Indications
    Chronic cancer pain
  491. Methimazole Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid > tablet: 5 mg; 10 mg
    Indications
    Thyrotoxicosis
  492. Methionine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg (DL)
    Indications
    Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs
  493. Methotrexate Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
    • Oral > Solid: 2.5 mg (as sodium salt)
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant trophoblastic neoplasms of placenta Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)
    Indications
    Psoriasis of unspecified type
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Indications
    Rheumatoid arthritis, serology unspecified
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: pre-filled syringe in multiple strengths
    Indications
    Crohn disease site Psoriatic arthritis
    Section
    Medicines for juvenile joint diseases
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Indications
    Juvenile idiopathic arthritis
  494. Methoxy polyethylene glycol-epoetin beta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  495. Methyldopa Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 250 mg
    Indications
    Essential hypertension Gestational hypertension
  496. Methylergometrine Informations générales
    Section
    Uterotonics
    Indications
    Therapeutic equivalent to ergometrine pour Postpartum haemorrhage
  497. Methylphenidate Informations générales
    Section
    Medicines for mental and behavioural disorders
    • Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 20 mg (hydrochloride); 18 mg extended-release (hydrochloride); 27 mg extended-release (hydrochloride); 36 mg extended-release (hydrochloride); 54 mg extended-release (hydrochloride); 72 mg extended-release (hydrochloride)
    • Oral > Solid > capsule: 10 to 60 mg extended-release (hydrochloride)
    Indications
    Attention deficit hyperactivity disorder
  498. Methylprednisolone Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)
    • Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection
    Indications
    Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified
  499. Methylthioninium chloride Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
    Indications
    Acquired methaemoglobinaemia
  500. Metoclopramide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (scored) (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Nausea or vomiting
  501. Metoprolol Informations générales
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol pour Heart failure
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Essential hypertension
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Cardiac arrhythmia
  502. Metronidazole Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
    • Local > Rectal > Suppository: 500 mg; 1 g
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    Indications
    Premier choix
    Intestinal infections due to Clostridioides difficile Trichomoniasis co-prescrite avec cefazolin Other specified prophylactic measures co-prescrite avec cefotaxime Peritonitis (severe) co-prescrite avec cefotaxime Peritonitis (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (severe) co-prescrite avec ceftriaxone Necrotising fasciitis co-prescrite avec ceftriaxone Peritonitis (severe) co-prescrite avec ceftriaxone Peritoneal abscess (mild-moderate) co-prescrite avec ceftriaxone Peritoneal abscess (severe) co-prescrite avec ceftriaxone Peritonitis (mild-moderate)
    Second choix
    co-prescrite avec ciprofloxacin Peritonitis (mild-moderate) co-prescrite avec ciprofloxacin Peritoneal abscess (mild-moderate)
    Autres indications
    Bacterial infection of unspecified site
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Parenteral > General injections > unspecified: 500 mg in 100 mL vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    Indications
    Amoebiasis
  503. Micafungin Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection
    Indications
    Systemic or invasive candidosis
  504. Miconazole Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 2% (nitrate)
    • Local > Topical > Ointment: 2% (nitrate)
    Indications
    Fungal infection of the skin
  505. Midazolam Informations générales
    Section
    Antiseizure medicines
    • Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
    • Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
    Indications
    Status epilepticus Therapeutic equivalent to lorazepam pour Status epilepticus
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg per mL in 5 vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid > dosage form: 15 mg; 7.5 mg
    Indications
    Sedative-hypnotic and anxiolytic drugs
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial
    • Local > Buccal > Solution: ; 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
    • Oral > Solid > dosage form: 7.5 mg; 15 mg
    Indications
    Palliative care
  506. Mifepristone - misoprostol Informations générales
    Section
    Medicines for medical abortion
    • Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
    Indications
    Unspecified time of fetal death, cause not specified Induced abortion
  507. Miltefosine Informations générales
    Section
    Antileishmaniasis medicines
    • Oral > Solid: 10 mg; 50 mg
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  508. Misoprostol Informations générales
    Section
    Uterotonics
    • Local > Vaginal > tablet: 25 µg
    • Oral > Solid: 200 µg
    Indications
    Unspecified obstetric condition Postpartum haemorrhage
    Section
    Medicines for medical abortion
    • Oral > Solid > tablet: 200 µg
    Indications
    Spontaneous abortion, incomplete, without complication
  509. Mometasone Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  510. Mometasone + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  511. Morphine Informations générales
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    Indications
    Opioids or related analgesics and agents affecting opioid receptors
    Section
    Opioid analgesics
    • Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate); 5 mg per 5 mL (morphine hydrochloride or morphine sulfate)
    • Parenteral > General injections > unspecified: 1 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    • Oral > Solid > tablet: 10 mg immediate release (morphine sulfate)
    • Oral > Solid > dosage form: 5 mg slow-release (morphine hydrochloride or morphine sulfate); 10 mg slow-release (morphine hydrochloride or morphine sulfate); 30 mg slow-release (morphine hydrochloride or morphine sulfate); 60 mg slow-release (morphine hydrochloride or morphine sulfate); 100 mg slow-release (morphine hydrochloride or morphine sulfate); 200 mg slow-release (morphine hydrochloride or morphine sulfate)
    • Oral > Solid > granules: 20 mg (morphine sulfate); 30 mg (morphine sulfate); 60 mg (morphine sulfate); 100 mg (morphine sulfate); 200 mg (morphine sulfate)
    Indications
    Pain
  512. Moxidectin Informations générales
    Section
    Antifilarials
    • Oral > Solid > tablet: 2 mg
    Indications
    Therapeutic equivalent to ivermectin pour Lymphatic filariasis Therapeutic equivalent to ivermectin pour Onchocerciasis
  513. Moxifloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 400 mg
    • Oral > Solid > dispersible tablet: 100 mg
    Indications
    Tuberculosis Multi-drug resistant Mycobacterium tuberculosis
  514. Mpox vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  515. Multiple micronutrient powder Informations générales
    Section
    Vitamins and minerals
    • Sachets containing:
    • - iron (elemental) 12.5 mg (as coated ferrous fumarate)
    • - zinc (elemental) 5 mg
    • - vitamin A 300 micrograms
    • - with or without other micronutrients at recommended daily values
    Indications
    Iron deficiency anaemia
  516. Multiple micronutrient supplement Informations générales
    Section
    Other medicines administered to the mother
    • Tablet containing:
    • Vit A: 800 mcg retinol activity equivalent
    • Vit C: 70 mg
    • Vit D: 5 mcg (200 IU)
    • Vit E: 10 mg alpha tocopherol equivalent
    • Vit B1: 1.4 mg
    • Vit B2: 1.4 mg
    • Vit B3: 18 mg niacin equivalent
    • Vit B6: 1.9 mg
    • Folic acid: 400 mcg
    • Vit B12: 2.6 mcg
    • Iron: 30 mg
    • Iodine: 150 mcg
    • Zinc: 15 mg
    • Selenium: 65 mcg
    • Copper: 2 mg
    Indications
    Maternal care for other specified conditions predominantly related to pregnancy
  517. Mumps vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against mumps alone
  518. Mupirocin Informations générales
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 2% (as mupirocin calcium)
    • Local > Topical > Ointment: 2%
    Indications
    Superficial bacterial folliculitis Impetigo
  519. Nadroparin Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism
  520. Nalidixic acid Informations générales
    Section
    Anti-infective medicines
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Shigella resistant to unspecified antibiotic
  521. Naloxone Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
    Indications
    Unintentional exposure to or harmful effects of opioids or related analgesics
  522. Naltrexone Informations générales
    Section
    Medicines for alcohol use disorders
    • Parenteral > General injections > IM: 380 mg in vial (extended-release)
    • Oral > Solid > tablet: 50 mg
    Indications
    Disorders due to use of alcohol
  523. Naproxen Informations générales
    Section
    Medicines for acute migraine attacks
    Indications
    Therapeutic equivalent to ibuprofen pour Migraine
  524. Natamycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Suspension: 5% eye drops
    Indications
    Infectious keratitis
  525. Nelfinavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 250 mg (as mesilate)
    • Oral > Other: 50 mg per g oral powder
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  526. Neostigmine Informations générales
    Section
    Medicines for myasthenia gravis
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
    • Oral > Solid > tablet: 15 mg (neostigmine bromide)
    Indications
    Myasthenia gravis
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
    • Oral > Solid > tablet: 15 mg (neostigmine bromide)
    Indications
    Myasthenia gravis Anticholinesterase reversible
  527. Netilmicin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
  528. Nevirapine Informations générales
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid > dispersible tablet: 50 mg
    • Oral > Solid > tablet: 200 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  529. Niclosamide Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid: 500 mg tablet (chewable)
    Indications
    Hymenolepiasis Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium
  530. Nicotinamide Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Pellagra
  531. Nicotine replacement therapy Informations générales
    Section
    Medicines for nicotine use disorders
    • Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
    • Oral > Solid > lozenge: 2 mg; 4 mg lozenge
    • Local > Buccal > Oral spray: 1 mg per actuation
    • Local > Buccal > Chewing gum: 2 mg; 4 mg
    Indications
    Nicotine dependence
  532. Nifedipine Informations générales
    Section
    Antioxytocics (tocolytics)
    • Oral > Solid: 10 mg (immediate-release)
    Indications
    Preterm labour without delivery
    Section
    Antianginal medicines
    • Oral > Solid: 10 mg
    Indications
    Angina pectoris
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg tablet; sustained-release formulations
    Indications
    Essential hypertension
  533. Nifurtimox Informations générales
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
    Indications
    Chagas disease
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
    Indications
    Gambiense trypanosomiasis
  534. Nilotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid > capsule: 150 mg; 200 mg
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  535. Nilutamide Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate
  536. Nitrofurantoin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Premier choix
    Infectious cystitis
  537. Nitrous oxide Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
    Indications
    Anaesthetics and therapeutic gases
  538. Nivolumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab pour Melanoma of skin Other specified malignant neoplasms of bronchus or lung Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Adenocarcinoma of oesophagogastric junction Adenocarcinoma of stomach
  539. Norethisterone Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 350 µg
    Indications
    Contact with health services for contraceptive management
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate pour Excessive menstruation with irregular cycle
  540. Norethisterone enantate Informations générales
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
    Indications
    Contact with health services for reasons associated with reproduction
  541. Normal immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
    Indications
    Primary immunodeficiencies Langerhans cell histiocytosis Mucocutaneous lymph node syndrome
    Section
    Medicines for Guillain-Barré syndrome
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    Indications
    Acute inflammatory demyelinating polyneuropathy
  542. Nystatin Informations générales
    Section
    Antifungal medicines
    • Oral > Liquid: 100000 IU per mL
    • Local > Topical > Other: 100000 IU pessary
    • Oral > Solid > dosage form: 500000 IU
    • Oral > Solid > lozenge: 100000 IU
    Indications
    Candidosis
  543. Ocrelizumab Informations générales
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL vial
    • Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution
    Indications
    Relapsing-remitting multiple sclerosis Multiple sclerosis
  544. Octreotide Informations générales
    Section
    Medicines for disorders of the pituitary hormone system
    • Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
    • Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
    Indications
    Acromegaly or pituitary gigantism
  545. Ofloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Ear, nose and throat medicines [c]
    Indications
    Therapeutic equivalent to ciprofloxacin pour Infectious diseases of external ear
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3%
    Indications
    Other specified conjunctivitis Infectious keratitis
  546. Olanzapine Informations générales
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 10 mg in vial powder for injection
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  547. Omadacycline Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 100 mg lyophilized powder for injection
    • Oral > Solid: 300 mg
    Indications
    Methicillin resistant Staphylococcus aureus
  548. Ombitasvir + paritaprevir + ritonavir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet
    Indications
    Chronic hepatitis C
  549. Omeprazole Informations générales
    Section
    Antiulcer medicines
    • Parenteral > General injections > IV: 40 mg in vial
    • Oral > Liquid: 1 mg per mL powder for oral liquid; 4 mg per mL powder for oral liquid
    • Oral > Solid > dosage form: 10 mg; 20 mg; 40 mg
    Indications
    Gastrointestinal bleeding Peptic ulcer, site unspecified Gastro-oesophageal reflux disease
  550. Ondansetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule (as hydrochloride dihydrate)
    • Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)
    • Oral > Solid: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule
    • Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)
    • Oral > Solid > dosage form: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate); 24 mg (as hydrochloride dihydrate)
    Indications
    Nausea or vomiting
  551. Oral rehydration salts Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq or mmol/L
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mEq or mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
    Section
    Oral rehydration
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq or mmol/L
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mEq or mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Diarrhoea
  552. Oral rehydration salts - zinc sulfate Informations générales
    Section
    Medicines used in diarrhoea
    • Oral > Other: ORS powder for dilution and zinc sulfate dispersible tablet 20 mg (co-packaged)
    Indications
    Diarrhoea
  553. Oseltamivir Informations générales
    Section
    Other antivirals
    • Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid
    • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
    Indications
    Influenza due to identified seasonal influenza virus
  554. Osimertinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)
    Indications
    Other specified malignant neoplasms of bronchus or lung
  555. Oxaliplatin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  556. Oxamniquine Informations générales
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid > capsule: 250 mg
    Indications
    Schistosomiasis due to Schistosoma mansoni
  557. Oxazolindinones Informations générales
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  558. Oxycodone Informations générales
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine pour Pain
  559. Oxygen Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation: (medical gas)
    Indications
    Anaesthetics and therapeutic gases
    Section
    Medical gases
    • Respiratory > Inhalation:
    Indications
    Respiratory failure as acute or chronic
  560. Oxytetracycline Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma
  561. Oxytocin Informations générales
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 10 IU per mL
    Indications
    Postpartum haemorrhage
  562. P-aminosalicylate sodium Informations générales
    Section
    Antituberculosis medicines
    • Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  563. P-aminosalicylic acid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 4 g granules in sachet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  565. Palbociclib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 75 mg; 100 mg; 125 mg
    Indications
    Other specified malignant neoplasms of breast
  566. Paliperidone Informations générales
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  567. Palonosetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  568. Pancreatic enzymes Informations générales
    Section
    Gastrointestinal medicines
    • Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units.
    • *Units expressed in Ph. Eur
    Indications
    Enzyme intestinal
    Section
    Medicines for cystic fibrosis
    • Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units.
    • *Units expressed in Ph. Eur
    Indications
    Cystic fibrosis
  569. Panitumumab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial
    Indications
    Other specified malignant neoplasms of large intestine
  570. Paracetamol (acetaminophen) Informations générales
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 100 mg; 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Pain
    Section
    Medicines for acute migraine attacks
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Migraine
  571. Paromomycin Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
    Indications
    Visceral leishmaniasis
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 125 mg per 5 mL as sulfate
    • Oral > Solid: 250 mg as sulfate
    Indications
    Amoebiasis
  572. Pegaspargase Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  573. Pegfilgrastim Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  574. Pegylated interferon alfa (2a) Informations générales
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  575. Pegylated interferon alfa (2b) Informations générales
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  576. Pembrolizumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion
    Indications
    Melanoma of skin Malignant neoplasms of cervix uteri Other specified malignant neoplasms of large intestine Other specified malignant neoplasms of bronchus or lung Adenocarcinoma of stomach Squamous cell carcinoma of hypopharynx and variants Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Carcinoma of breast, specialised type Squamous cell carcinoma of nasopharynx Squamous cell carcinoma of oesophagus Malignant neoplasms of oesophagogastric junction Therapeutic equivalent to nivolumab pour Melanoma of skin
  577. Penicillamine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 250 mg
    Indications
    Rheumatoid arthritis, serology unspecified
  578. Pentamidine Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)
    Indications
    Visceral leishmaniasis
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)
    Indications
    Pneumocystosis
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection
    Indications
    Gambiense trypanosomiasis
  579. Perindopril + amlodipine + indapamide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid > dosage form: 5 mg (arginine) + 5 mg + 1.25 mg; 5 mg (arginine) + 10 mg + 1.25 mg; 10 mg (arginine) + 5 mg + 2.5 mg; 10 mg (arginine) + 10 mg + 2.5 mg
    Indications
    Essential hypertension
  580. Permethrin Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 1%
    • Local > Topical > Cream: 5%
    Indications
    Pediculosis corporis Pediculosis capitis Scabies
  581. Pertussis vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against pertussis alone
  582. Pertuzumab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution
    Indications
    Carcinoma of breast, specialised type
  583. Phenelzine Informations générales
    Section
    Medicines for depressive disorders
    • Oral > Solid > dosage form: 15 mg (as sulfate)
    Indications
    Other specified depressive disorders
  584. Phenobarbital Informations générales
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)
    • Oral > Liquid: 15 mg per 5 mL
    • Oral > Solid > tablet: 15 mg; 30 mg; 60 mg; 100 mg
    Indications
    Status epilepticus Epilepsy or seizures
  585. Phenoxymethylpenicillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt) tablet
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
    Indications
    Premier choix
    Acute pharyngitis Periapical abscess without sinus Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
    Autres indications
    Bacterial infection of unspecified site
  586. Phenytoin Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 30 mg per 5 mL (phenytoin)
    • Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)
    • Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
    • Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)
    Indications
    Epilepsy or seizures
  587. Phosphorus Informations générales
    Section
    Medicines for endocrine disorders
    • Oral > Other: 500 mg in sachet (elemental phosphorus) granules
    • Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)
    Indications
    Hypophosphataemic rickets
  588. Phytomenadione Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1 mg per 0.5 mL in ampoule; 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution
    • Oral > Solid > tablet: 5 mg tablet
    Indications
    Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors Haemorrhagic or haematological disorders of fetus or newborn
  589. Pilocarpine Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
    Indications
    Acute angle closure with pupillary block Ocular hypertension Primary open-angle glaucoma
  590. Piperacillin + tazobactam Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    Premier choix
    Peritoneal abscess (severe) Other specified pneumonia (Hospital-acquired pneumonia) Neutropenia (high-risk) Peritonitis (severe) co-prescrite avec clindamycin Necrotising fasciitis
  591. Platelets Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  592. Plazomicin Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  593. Pneumococcal vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  594. Podophyllotoxin Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to podophyllum resin pour Anogenital warts Therapeutic equivalent to podophyllum resin pour Plantar warts
  595. Podophyllum resin Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 10 to 25%
    Indications
    Anogenital warts Plantar warts
  596. Poliomyelitis vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against poliomyelitis
  597. Polygeline Informations générales
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 3.5% injectable solution
    • Parenteral > General injections > IV: 3.5% in solution
    Indications
    Therapeutic equivalent to dextran 70 pour Hypovolaemia Hypovolaemia
  598. Polymyxin B (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  599. Polymyxins Informations générales
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  600. Porcatant alfa Informations générales
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 80 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  601. Potassium chloride Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Oral > Liquid: powder for solution
    Indications
    Hypokalaemia
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
    Indications
    Hypokalaemia
  602. Potassium ferric hexacyanoferrate (Prussian blue) Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: Powder for oral administration
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  603. Potassium iodide Informations générales
    Section
    Antifungal medicines
    • Local > Topical > Solution: Saturated solution
    Indications
    Sporotrichosis
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid > tablet: 65 mg (scored)
    Indications
    Thyrotoxicosis
  604. Potassium permanganate Informations générales
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Solution: aqueous solution: 1:10 000
    Indications
    Tropical phagedaenic ulcer Pemphigus Other specified pyogenic bacterial infection of skin and subcutaneous tissue Impetigo
  605. Povidone iodine Informations générales
    Section
    Antiseptics
    • Local > Topical > Solution: 10% (equivalent to 1% available iodine)
    Indications
    Povidone iodine
  606. Pralidoxime Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • .
    Indications
    Exposure to or harmful effects of undetermined intent of pesticides
  607. Pramipexole Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release
    Indications
    Parkinson disease
  608. Pravastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  609. Praziquantel Informations générales
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Taeniasis due to Taenia saginata Taeniasis due to Taenia solium Hymenolepiasis Diphyllobothriasis
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Cysticercosis of central nervous system
  610. Precipitated sulfur Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Ointment:
    Indications
    Therapeutic equivalent to benzyl benzoate pour Pthiriasis Therapeutic equivalent to benzyl benzoate pour Pediculosis corporis Therapeutic equivalent to benzyl benzoate pour Pediculosis capitis Therapeutic equivalent to benzyl benzoate pour Scabies
  611. Prednisolone Informations générales
    Section
    Hormones and antihormones
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Plasma cell myeloma Follicular lymphoma Malignant neoplasms of prostate Hodgkin lymphoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphoma, not otherwise specified
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Retention enema:
    • Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)
    Indications
    Therapeutic equivalent to hydrocortisone pour Crohn disease site Crohn disease site Ulcerative colitis
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
    Indications
    Scleritis Anterior uveitis
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 1 mg
    Indications
    Adrenocortical insufficiency
    Section
    Medicines for cluster headache
    • Oral > Solid > tablet: 25 mg; 5 mg
    Indications
    Trigeminal autonomic cephalalgias
  612. Prednisone Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to prednisolone pour Plasma cell myeloma Therapeutic equivalent to prednisolone pour Follicular lymphoma Therapeutic equivalent to prednisolone pour Malignant neoplasms of prostate Therapeutic equivalent to prednisolone pour Hodgkin lymphoma Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone pour Langerhans cell histiocytosis Therapeutic equivalent to prednisolone pour Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone pour Diffuse large B-cell lymphoma, not otherwise specified
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to prednisolone pour Allergic or hypersensitivity conditions of unspecified type
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 1 mg
    Indications
    Therapeutic equivalent to prednisolone pour Adrenocortical insufficiency
  613. Pretomanid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 200 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  614. Primaquine Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 7.5 mg (as phosphate); 15 mg (as phosphate)
    Indications
    Malaria due to Plasmodium ovale Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  615. Probenecid Informations générales
    Section
    Medicines used to treat gout
    • Oral > Solid: 500 mg
    Indications
    Gout
  616. Procainamide Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride)
    • Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)
    Indications
    Cardiac arrhythmia
  617. Procaine benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
    Premier choix
    Congenital syphilis [children]
    Second choix
    Syphilis
  618. Procarbazine Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    • Oral > Solid > capsule: 50 mg (as hydrochloride)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Hodgkin lymphoma
  619. Progesterone vaginal ring Informations générales
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
    Indications
    Contact with health services for contraceptive management
  620. Proguanil Informations générales
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid: 100 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  621. Promethazine Informations générales
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL (hydrochloride)
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule
    Indications
    Nausea or vomiting
  622. Propanol Informations générales
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to ethanol pour Denatured alcohol
  623. Propofol Informations générales
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL
    Indications
    Anaesthetics and therapeutic gases
  624. Propranolol Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)
    Indications
    Essential hypertension
    Section
    Antianginal medicines
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
    • Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)
    Indications
    Angina pectoris
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
    • Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)
    Indications
    Cardiac arrhythmia
    Section
    Medicines for migraine prophylaxis
    • Oral > Solid > tablet: 40 mg (hydrochloride); 10 mg (hydrochloride)
    Indications
    Migraine
  625. Propylthiouracil Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 mg
    Indications
    Thyrotoxicosis
  626. Protamine sulfate Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial
    Indications
    Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors
  627. Protionamide Informations générales
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to ethionamide pour Multi-drug resistant Mycobacterium tuberculosis
  628. Pyrantel Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)
    Indications
    Ascariasis Trichuriasis Enterobiasis Hookworm diseases
  629. Pyrazinamide Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 400 mg; 500 mg
    Indications
    Tuberculosis
  630. Pyridostigmine Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)
    • Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)
    Indications
    Myasthenia gravis
    Section
    Medicines for myasthenia gravis
    • Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)
    • Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)
    Indications
    Myasthenia gravis
  631. Pyridoxine Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid > tablet: 25 mg (hydrochloride); 10 mg (hydrochloride)
    Indications
    Other specified polyneuropathy Vitamin B6 deficiency Sideroblastic anaemia
  632. Pyrimethamine Informations générales
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 25 mg
    Indications
    Toxoplasmosis
  633. Quetiapine Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)
    Indications
    Bipolar or related disorders
  634. Quinidine Informations générales
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 200 mg (sulfate)
    Indications
    Cardiac arrhythmia
  635. Quinine Informations générales
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion
    Indications
    Malaria due to Plasmodium falciparum
  636. Rabies vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rabies
  637. Raltegravir Informations générales
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Liquid: 100 mg granules for oral suspension
    • Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  638. Ranibizumab Informations générales
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • .
    Indications
    Retinal venous occlusions Diabetic macular oedema Degenerative high myopia Age related macular degeneration
  639. Ranitidine Informations générales
    Section
    Antiulcer medicines
    • Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
    Indications
    Gastro-oesophageal reflux disease Peptic ulcer, site unspecified
  640. Rasburicase Informations générales
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution
    Indications
    Tumour lysis syndrome
  641. Ravidasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg
    Indications
    Chronic hepatitis C
  642. Ready to use therapeutic food Informations générales
    Section
    Therapeutic foods
    • Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.
    Indications
    Acute malnutrition in infants, children or adolescents
  643. Realgar-indigo naturalis formulation Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  644. Red blood cells Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  645. Resin-based composite (high-viscosity) Informations générales
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use capsule or multi-use syringe
    Indications
    Dental caries
  646. Resin-based composite (low-viscosity) Informations générales
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use applicator or multi-use bottle
    Indications
    Dental caries
  647. Respiratory syncytial virus vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  648. Retinol Informations générales
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 50000 IU per mL in 2 mL ampoule or vial water-miscible (as palmitate)
    • Oral > Liquid: 100000 IU per mL (as palmitate or acetate)
    • Oral > Solid > capsule: 200000 IU (as palmitate or acetate) soft capsule; 50000 IU (as palmitate); 100000 IU (as palmitate or acetate) soft capsule
    Indications
    Vitamin A deficiency
  649. Ribavirin Informations générales
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Chronic hepatitis C
    Section
    Other antivirals
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Viral haemorrhagic fever, not elsewhere classified
  650. Ribociclib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast
  651. Riboflavin Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 5 mg
    Indications
    Vitamin B2 deficiency
  652. Rifabutin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
    Tuberculosis
  653. Rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    • Parenteral > General injections > IV: 600 mg in vial powder for injection
    Indications
    Tuberculosis Other specified tuberculosis
    Section
    Antileprosy medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Leprosy
  654. Rifapentine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 150 mg; 300 mg
    • Oral > Solid > dispersible tablet: 150 mg
    Indications
    Tuberculosis Latent tuberculosis
  655. Risdiplam Informations générales
    Section
    Medicines for neurological disorders
    • Oral > Liquid: 0.75 mg per mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 5 mg
    Indications
    Spinal muscular atrophy
  656. Risperidone Informations générales
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
    • Parenteral > General injections > IM:
    Indications
    Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone pour Schizophrenia or other primary psychotic disorders
  657. Ritonavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  658. Rituximab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphoma, not otherwise specified
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
    Indications
    Multiple sclerosis
  659. Rivaroxaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  660. Ropinirole Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release
    Indications
    Parkinson disease
  661. Rotavirus vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  662. Rubella vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rubella alone
  663. Salbutamol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > IV: 500 µg per mL in 1 mL ampoule (as sulfate); 500 µg per mL in 5 mL ampoule (as sulfate)
    • Respiratory > Inhalation > solution: 100 µg per actuation in pressurized metered dose inhaler (as sulfate); 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers
    Indications
    Chronic obstructive pulmonary disease Asthma
  664. Salicylic acid Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses
  665. Saquinavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 200 mg; 500 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  666. Selenium sulfide Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Suspension: 2% detergent-based
    Indications
    Seborrhoeic dermatitis Pityriasis versicolor
  667. Semaglutide Informations générales
    Section
    Hypoglycaemic agents
    • Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution
    • Oral > Solid > tablet: 3 mg
    • Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL
    Indications
    Obesity Type 2 diabetes mellitus
  668. Senna Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 7.5 mg per 5 mL oral liquid
    Indications
    Palliative care
    Section
    Laxatives
    • Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)
    Indications
    Constipation
  669. Sevoflurane Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  670. Silver diamine fluoride Informations générales
    Section
    Dental medicines and preparations
    • Local > Dental > Solution: 38% w/v
    Indications
    Dental caries
  671. Silver nitrate Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1%
    Indications
    Neonatal conjunctivitis or dacryocystitis
  672. Silver sulfadiazine Informations générales
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 1%
    Indications
    Burns
  673. Simeprevir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 150 mg
    Indications
    Chronic hepatitis C
  674. Simvastatin Informations générales
    Section
    Lipid-lowering agents
    • Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg
    Indications
    Mixed hyperlipidaemia Coronary atherosclerosis
    Section
    Medicines for endocrine disorders
    • Oral > Solid: 20 mg
    Indications
    Polycystic ovary syndrome
  675. Smallpox vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  676. Snake antivenom Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • .
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  677. Sodium calcium edetate Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  678. Sodium chloride Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  679. Sodium hyaluronate Informations générales
    Section
    Ophthalmological preparations
    Indications
    Therapeutic equivalent to hypromellose pour Keratoconjunctivitis sicca
  680. Sodium hydrogen carbonate Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)
    Indications
    Acidosis
  681. Sodium nitrite Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  682. Sodium nitroprusside Informations générales
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 50 mg in ampoule powder for infusion
    Indications
    Hypertensive crisis
  683. Sodium stibogluconate Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  684. Sodium thiosulfate Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Solution: 15%
    Indications
    Pityriasis versicolor
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  685. Sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg; 400 mg
    • Oral > Solid > granules: 200 mg in sachet
    Indications
    Chronic hepatitis C
  686. Sofosbuvir + velpatasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
    • Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet
    Indications
    Chronic hepatitis C
  687. Somatropin Informations générales
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge
    Indications
    Hypoglycaemia without associated diabetes
  688. Spectinomycin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
    Second choix
    Gonococcal infection
    Autres indications
    Bacterial infection of unspecified site
  689. Spironolactone Informations générales
    Section
    Medicines used in heart failure
    • Oral > Solid > tablet: 25 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Oral > Liquid: 25 mg per 5 mL
    • Oral > Solid > tablet: 25 mg; 12.5 mg
    Indications
    Oedema Ascites
  690. Stavudine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 5 mg per 5 mL powder for oral solution
    • Oral > Solid: 15 mg; 20 mg; 30 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  691. Streptokinase Informations générales
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 1.5 million IU in vial powder for injection
    Indications
    Acute myocardial infarction
  692. Streptomycin (injection) Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  693. Succimer Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 100 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  694. Sulfacetamide Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 10% (sodium salt)
    Indications
    Other specified conjunctivitis
  695. Sulfadiazine Informations générales
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 500 mg
    Indications
    Toxoplasmosis
    Section
    Anti-infective medicines
    • Oral > Solid: 500 mg
    • Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)
    Indications
    Bacterial infection of unspecified site
  696. Sulfadimidine Informations générales
    Section
    Anti-infective medicines
    • Oral > Liquid: 500 mg per 5 mL
    • Oral > Solid: 500 mg
    • Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)
    Indications
    Bacterial infection of unspecified site
  697. Sulfadoxine + pyrimethamine Informations générales
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 500 mg + 25 mg tablet
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid: 500 mg + 25 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet
    Indications
    Malaria
  698. Sulfamethoxazole + trimethoprim Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    Premier choix
    Infectious cystitis
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent
    Autres indications
    Bacterial infection of unspecified site
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    Pneumocystosis
  699. Sulfasalazine Informations générales
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 500 mg
    Indications
    Rheumatoid arthritis, serology unspecified
    Section
    Anti-inflammatory medicines
    • Oral > Solid: 500 mg
    • Local > Rectal > Suppository: 500 mg
    • Local > Rectal > Retention enema: 3 g per 100 mL
    Indications
    Crohn disease site Ulcerative colitis
  700. Sumatriptan Informations générales
    Section
    Medicines for acute migraine attacks
    • Oral > Solid > tablet: 50 mg
    Indications
    Migraine
    Section
    Medicines for cluster headache
    • Parenteral > General injections > SC: 6 mg per 0.5 mL in pre-filled pen; 6 mg per 0.5 mL in pre-filled syringe
    Indications
    Trigeminal autonomic cephalalgias
  701. Sunscreen, broad-spectrum Informations générales
    Section
    Dermatological medicines
    • Topical cream, lotion, gel, ointment, spray with sun protection factor ≥ 50.
    Indications
    Xeroderma pigmentosum
    Section
    Dermatological medicines > Sunscreens
    • Topical:
    • Therapeutic broad-spectrum sunscreens should contain proven active ingredients in appropriate amounts to absorb or filter UVA and UVB radiation, and have a high sun protection factor (SPF).
    Indications
    Albinism or other specified genetically-determined hypomelanotic disorders
  702. Suramin sodium Informations générales
    Section
    Antifilarials
    • Parenteral > General injections > IV: 1 g in vial
    Indications
    Filariasis
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IV: 1 g in vial
    Indications
    Rhodesiense trypanosomiasis
  703. Suxamethonium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (chloride)
    Indications
    Muscle relaxants
  704. Tacalcitol Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to calcipotriol pour Psoriasis of unspecified type
  705. Tacrolimus Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
    • Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
    • Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)
    Indications
    Failure or rejection of transplanted organs or tissues
  706. Tamoxifen Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  707. Tedizolid Informations générales
    Section
    Reserve group antibiotics
    Indications
    Therapeutic equivalent to linezolid pour Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Enterococcus
  708. Telmisartan + amlodipine Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg
    Indications
    Essential hypertension
  709. Telmisartan + hydrochlorothiazide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
    Indications
    Essential hypertension
  710. Temozolomide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    • Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg
    Indications
    Ewing sarcoma of bone and articular cartilage of unspecified sites Other specified gliomas of brain Unspecified malignant neoplasms of ill-defined or unspecified sites Neuroblastoma, NOS
  711. Tenofovir alafenamide Informations générales
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 25 mg
    Indications
    Chronic hepatitis B
  712. Tenofovir disoproxil fumarate Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Chronic hepatitis B
  713. Terbinafine Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 1% terbinafine hydrochloride
    • Local > Topical > Ointment: 1% terbinafine hydrochloride
    Indications
    Fungal infection of the skin
  714. Terbutaline Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to salbutamol pour Chronic obstructive pulmonary disease Therapeutic equivalent to salbutamol pour Asthma
  715. Terizidone Informations générales
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to cycloserine pour Multi-drug resistant Mycobacterium tuberculosis
  716. Testosterone Informations générales
    Section
    Androgens
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
    Indications
    Testicular dysfunction or testosterone-related disorders
  717. Tetanus antitoxin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 50000 IU in vial
    Indications
    Tetanus
  718. Tetanus vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tetanus alone
  719. Tetracaine Informations générales
    Section
    Ophthalmological preparations > Local anaesthetics
    • Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)
    Indications
    Local anaesthetics
  720. Tetracycline Informations générales
    Section
    Access group antibiotics
    • Oral > Solid: 250 mg (hydrochloride)
    Indications
    Bacterial infection of unspecified site
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)
    Indications
    Neonatal conjunctivitis or dacryocystitis Other specified conjunctivitis Infectious keratitis Infectious blepharitis Trachoma
  721. Thalidomide Informations générales
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  722. Thiamine Informations générales
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 50 mg per mL in ampoule or vial (hydrochloride)
    • Oral > Solid > tablet: 50 mg (hydrochloride)
    Indications
    Vitamin B1 deficiency
  723. Thiopental Informations générales
    Section
    General anaesthetics and oxygen > Injectable medicines
    Indications
    Therapeutic equivalent to propofol pour Anaesthetics and therapeutic gases
  724. Ticagrelor Informations générales
    Section
    Anti-platelet medicines
    • Oral > Solid > tablet: 60 mg; 90 mg
    Indications
    Acute ischaemic heart disease Presence of coronary angioplasty implant or graft
  725. Tick-borne encephalitis vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against arthropod-borne viral encephalitis
  726. Tigecycline Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    Indications
    Other specified bacterial diseases
  727. Timolol Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)
    Indications
    Primary open-angle glaucoma Ocular hypertension
  728. Tinidazole Informations générales
    Section
    Antiamoebic and antigiardiasis medicines
    Indications
    Therapeutic equivalent to metronidazole pour Amoebiasis
  729. Tioguanine Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  730. Tiotropium bromide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > powder: 18 µg in capsule
    • Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler
    Indications
    Chronic obstructive pulmonary disease
  731. Tirzepatide Informations générales
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide pour Obesity Therapeutic equivalent to semaglutide pour Type 2 diabetes mellitus
  732. Tisagenlecleucel Informations générales
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel pour Diffuse large B-cell lymphomas
  733. Tislelizumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 10 mL
    • Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion
    • Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
    Indications
    Malignant neoplasms of urinary tract Hodgkin lymphoma Other specified malignant neoplasms of bronchus or lung Squamous cell carcinoma of oesophagus
  734. Tobramycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
  735. Tocilizumab Informations générales
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial
    • Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe
    Indications
    Juvenile systemic arthritis
  736. Tolbutamide Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg
    Indications
    Type 2 diabetes mellitus
  737. Torasemide Informations générales
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide pour Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide pour Anuria or oliguria Therapeutic equivalent to furosemide pour Oedema
  738. Toripalimab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 240 mg per 6 mL in vial
    Indications
    Malignant neoplasms of nasopharynx Squamous cell carcinoma of oesophagus
  739. Tramadol Informations générales
    Section
    Opioid analgesics
    • Oral > Liquid: 100 mg per mL (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release
    • Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Chronic cancer pain
  740. Trametinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 0.5 mg; 2 mg
    Indications
    Other specified melanoma of skin
  741. Tranexamic acid Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Haemorrhage, not elsewhere classified
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Postpartum haemorrhage
  742. Trastuzumab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  743. Trastuzumab emtansine Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  744. Tremelimumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion
    Indications
    Hepatocellular carcinoma of liver Other specified malignant neoplasms of bronchus or lung
  745. Triamcinolone hexacetonide Informations générales
    Section
    Medicines for juvenile joint diseases
    • Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial
    Indications
    Juvenile idiopathic arthritis
  746. Triclabendazole Informations générales
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 250 mg (scored)
    Indications
    Paragonimiasis Fascioliasis
  747. Trihexyphenidyl Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)
    Indications
    Parkinson disease
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to biperiden pour Parkinson disease
  748. Trimethoprim Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 100 mg; 200 mg
    Indications
    Premier choix
    Infectious cystitis
  749. Triptorelin Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate
  750. Tropicamide Informations générales
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 0.5%
    Indications
    Cycloplegic drug
  751. Tropisetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  752. Tuberculin, purified protein derivative Informations générales
    Section
    Immunologicals > Diagnostic agents
    • Parenteral > Locoregional injections > Intradermal:
    Indications
    Mycobacterial diseases
  753. Tubocurarine Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)
    Indications
    Muscle relaxants
  754. Typhoid vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against typhoid-paratyphoid alone
  755. Ulipristal Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 mg tablet (ulipristal acetate)
    Indications
    Contact with health services for postcoital contraception
  756. Umeclidinium Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease
  757. Urea Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 10%; 5%
    • Local > Topical > Ointment: 10%; 5%
    Indications
    Xerosis cutis or asteatosis
    Section
    Dermatological medicines > Moisturizers
    • Local > Topical > Cream: 5 per %
    Indications
    Atopic eczema
  758. Ustekinumab Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen
    Indications
    Psoriasis of unspecified type
  759. Valaciclovir Informations générales
    Section
    Antiherpes medicines
    Indications
    Therapeutic equivalent to aciclovir pour Zoster Therapeutic equivalent to aciclovir pour Varicella Therapeutic equivalent to aciclovir pour Herpes simplex infections
    Section
    Medicines for viral central nervous system infections
    Indications
    Therapeutic equivalent to aciclovir pour Herpes simplex infections Therapeutic equivalent to aciclovir pour Zoster Therapeutic equivalent to aciclovir pour Varicella
  760. Valganciclovir Informations générales
    Section
    Other antivirals
    • Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution
    • Oral > Solid > tablet: 450 mg (as hydrochloride)
    Indications
    Cytomegaloviral retinitis
  761. Valproic acid (sodium valproate) Informations générales
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)
    Indications
    Bipolar or related disorders
    Section
    Antiseizure medicines
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule
    Indications
    Epilepsy or seizures Status epilepticus
  762. Valsartan + amlodipine + hydrochlorothiazide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid > dosage form: 160 mg + 5 mg + 12.5 mg; 160 mg + 5 mg + 25 mg; 160 mg + 10 mg + 12.5 mg; 160 mg + 10 mg + 25 mg; 320 mg + 10 mg + 25 mg
    Indications
    Essential hypertension
  763. Vancomycin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
    • Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    Indications
    Premier choix
    Necrotising fasciitis co-prescrite avec ceftazidime Endophthalmitis co-prescrite avec ceftriaxone Endophthalmitis
    Second choix
    Neutropenia (high-risk) Intestinal infections due to Clostridioides difficile
    Autres indications
    Methicillin resistant Staphylococcus aureus
  764. Varenicline Informations générales
    Section
    Medicines for nicotine use disorders
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Nicotine dependence
  765. Varicella vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  766. Vecuronium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)
    Indications
    Muscle relaxants
  767. Vemurafenib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin
  768. Verapamil Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Supraventricular tachyarrhythmia
    Section
    Antianginal medicines
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Angina pectoris
    Section
    Medicines for cluster headache
    • Oral > Solid > tablet: 120 mg (hydrochloride) (immediate-release); 40 mg (hydrochloride) (immediate-release); 80 mg (hydrochloride) (immediate-release); 120 mg (hydrochloride) (extended-release); 180 mg (hydrochloride) (extended-release); 240 mg (hydrochloride) (extended-release)
    Indications
    Trigeminal autonomic cephalalgias
  770. Vincristine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Retinoblastoma Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Langerhans cell histiocytosis Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphoma, not otherwise specified
  771. Vinorelbine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid > capsule: 20 mg; 30 mg; 80 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Rhabdomyosarcoma primary site
  772. Voriconazole Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection
    • Oral > Liquid: 40 mg per mL powder for oral liquid
    • Oral > Solid: 50 mg tablet; 200 mg tablet
    Indications
    Chronic pulmonary aspergillosis Invasive aspergillosis
  773. Warfarin Informations générales
    Section
    Medicines affecting coagulation
    • Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
    • Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
    Indications
    Other specified diseases of arteries or arterioles Venous thromboembolism Cerebral ischaemic stroke due to embolic occlusion Atrial fibrillation
  774. Water for injection Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous
    • Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule
    Indications
    Unspecified appropriateness of dosing or administration without injury or harm
  775. Whole blood Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  776. Xylometazoline Informations générales
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 0.05% equivalent to 0.5 mg per mL
    • Local > Nasal > Drops: 0.05% equivalent to 0.5 mg per mL
    Indications
    Nasal congestion
  777. Yellow fever vaccine Informations générales
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  778. Zanubrutinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 80 mg
    • Oral > Solid > capsule: 80 mg
    Indications
    Mantle cell lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to ibrutinib pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  779. Zidovudine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid > tablet: 300 mg
    • Oral > Solid > capsule: 250 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  780. Zinc sulfate Informations générales
    Section
    Medicines for diarrhoea
    • Oral > Solid > dispersible tablet: 20 mg (scored)
    Indications
    Diarrhoea
  781. Zoledronic acid Informations générales
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Osteogenesis imperfecta
  782. Zuclopenthixol decanoate Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to fluphenazine pour Schizophrenia or other primary psychotic disorders